US20090036324A1 - Arrays, substrates, devices, methods and systems for detecting target molecules - Google Patents

Arrays, substrates, devices, methods and systems for detecting target molecules Download PDF

Info

Publication number
US20090036324A1
US20090036324A1 US12/174,601 US17460108A US2009036324A1 US 20090036324 A1 US20090036324 A1 US 20090036324A1 US 17460108 A US17460108 A US 17460108A US 2009036324 A1 US2009036324 A1 US 2009036324A1
Authority
US
United States
Prior art keywords
array
protein
target
targets
microfluidic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/174,601
Other languages
English (en)
Inventor
Rong Fan
Habib Ahmad
James R. Heath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
California Institute of Technology CalTech
Original Assignee
California Institute of Technology CalTech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Institute of Technology CalTech filed Critical California Institute of Technology CalTech
Priority to US12/174,601 priority Critical patent/US20090036324A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Assignors: CALIFORNIA INSTITUTE OF TECHNOLOGY
Assigned to CALIFORNIA INSTITUTE OF TECHNOLOGY reassignment CALIFORNIA INSTITUTE OF TECHNOLOGY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AHMAD, HABIB, FAN, RONG, HEATH, JAMES R.
Publication of US20090036324A1 publication Critical patent/US20090036324A1/en
Priority to US14/694,340 priority patent/US20160011189A1/en
Priority to US15/359,464 priority patent/US10928389B2/en
Priority to US16/191,207 priority patent/US20190195869A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J19/0046—Sequential or parallel reactions, e.g. for the synthesis of polypeptides or polynucleotides; Apparatus and devices for combinatorial chemistry or for making molecular arrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502746—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by the means for controlling flow resistance, e.g. flow controllers, baffles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502753—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by bulk separation arrangements on lab-on-a-chip devices, e.g. for filtration or centrifugation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00277—Apparatus
    • B01J2219/0054—Means for coding or tagging the apparatus or the reagents
    • B01J2219/00547—Bar codes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00596—Solid-phase processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00583—Features relative to the processes being carried out
    • B01J2219/00603—Making arrays on substantially continuous surfaces
    • B01J2219/00605—Making arrays on substantially continuous surfaces the compounds being directly bound or immobilised to solid supports
    • B01J2219/00614—Delimitation of the attachment areas
    • B01J2219/00621—Delimitation of the attachment areas by physical means, e.g. trenches, raised areas
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00722—Nucleotides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/00725—Peptides
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718—Type of compounds synthesised
    • B01J2219/0072—Organic compounds
    • B01J2219/0074—Biological products
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/06—Auxiliary integrated devices, integrated components
    • B01L2300/0627—Sensor or part of a sensor is integrated
    • B01L2300/0636—Integrated biosensor, microarrays
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0864—Configuration of multiple channels and/or chambers in a single devices comprising only one inlet and multiple receiving wells, e.g. for separation, splitting
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2300/00—Additional constructional details
    • B01L2300/08—Geometry, shape and general structure
    • B01L2300/0861—Configuration of multiple channels and/or chambers in a single devices
    • B01L2300/0867—Multiple inlets and one sample wells, e.g. mixing, dilution
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/04—Moving fluids with specific forces or mechanical means
    • B01L2400/0475—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure
    • B01L2400/0487—Moving fluids with specific forces or mechanical means specific mechanical means and fluid pressure fluid pressure, pneumatics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L2400/00—Moving or stopping fluids
    • B01L2400/08—Regulating or influencing the flow resistance
    • B01L2400/084—Passive control of flow resistance
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5025—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures for parallel transport of multiple samples
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
    • B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
    • B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
    • B01L3/502—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures
    • B01L3/5027—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip
    • B01L3/502715—Containers for the purpose of retaining a material to be analysed, e.g. test tubes with fluid transport, e.g. in multi-compartment structures by integrated microfluidic structures, i.e. dimensions of channels and chambers are such that surface tension forces are important, e.g. lab-on-a-chip characterised by interfacing components, e.g. fluidic, electrical, optical or mechanical interfaces
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2458/00—Labels used in chemical analysis of biological material
    • G01N2458/10—Oligonucleotides as tagging agents for labelling antibodies

Definitions

  • the present disclosure relates to patterning of materials, performance of assays and in particular detection of target molecules in a sample. More specifically, it relates to arrays, devices, methods and systems for detecting a plurality of target molecules in a sample.
  • biomarkers Detection of target molecules and in particular of biomarkers has been a challenge in the field of biological molecule analysis. In particular, qualitative and quantitative detection of biomarkers is often a critical step in several applications ranging from diagnostics to fundamental biology studies.
  • detection of the multiple biomarkers is directed to identify a biological profile (e.g. proteome and/or metabolome) which can be associated to an indication of interest (e.g. a diagnostic indication).
  • a biological profile e.g. proteome and/or metabolome
  • Detection of multiple biomarkers is performed by several surface-bound assays known in the art.
  • capture agents e.g. primary antibodies
  • a surface e.g. a substrate surface
  • capture agent binding complexes are then detected, typically through further binding of the targets with labeling molecules (e.g. secondary antibodies coupled with fluorescent dyes).
  • a number of critical parameters is associated with successful execution of a surface-bound assay and include: a) sensitivity of the assay, or minimum concentration, of the biomolecule that can be detected, b) concentration range over which that biomolecule can be detected, c) numbers of different biomolecules that can simultaneously be detected, d) variability from measurement to measurement, e) numbers of different types of biomolecules (e.g. mRNAs, proteins, etc.) that can simultaneously be detected, f) minimum sample size required for the measurement, and g) speed at which the measurement can be performed.
  • Microfluidics-based assays are particularly attractive for applications where minimum sample size and short time of execution are desired, because they require only small amounts of biological materials and small amounts of capture agents, materials and associated reagents.
  • devices, methods and systems for detection of a plurality of targets that allow a fast and sensitive detection of a large number of multiple targets in a sample and/or provide results in an easily readable fashion.
  • an array for detecting at least one target in a sample, and in particular a plurality of targets in a sample comprises, at least one capture agent or component thereof attached to a substrate, the at least one capture agent capable of specifically binding the at least one target to form a capture agent target binding complex.
  • the at least one target can be a plurality of targets
  • the capture agent can be a plurality of capture agents, with each capture agent of the plurality of capture agents bindingly distinguishable and positionally distinguishable from another and capable of specifically binding each target of the plurality of targets to form a capture agent target binding complex.
  • a microfluidic device that comprises an array according to the present disclosure.
  • a system for the detection of a plurality of targets in a sample comprises an array disclosed herein and a device for detecting the barcoded pattern on the array.
  • a method for detecting a plurality of targets in a sample comprises: contacting said sample with an array herein disclosed for a time and under conditions to allow binding of said plurality of targets with said plurality of capture agents to form capture agent target binding complexes; and detecting said capture agent target binding complexes.
  • a substrate for detecting a target, and in particular a plurality of targets, in a sample.
  • the substrate is configured to allow attachment of the target on the substrate so that said target is detectable along substantially parallel lines forming a barcoded pattern.
  • a microfluidic device that comprises a substrate according to the present disclosure.
  • a system for the detection of a target, and in particular a plurality of targets, in a sample comprises a substrate disclosed herein and a device for detecting the barcoded pattern on the substrate.
  • a method for detecting a target and, in particular, a plurality of targets, in a sample comprises: contacting said sample with a substrate herein disclosed for a time and under conditions to allow binding of said target with said substrate; and detecting said target attached to the substrate.
  • a method to attach a molecule on a microfluidic support along a predetermined microfluidic pattern comprises: providing a mold comprising microfluidic channels, the microfluidic channels having an inlet and an outlet, the outlets of the channels configured to form part of the predetermined pattern, providing the support, said support suitable to be coupled with the mold, coupling the mold with the support, providing the molecule in the microfluidic channels for a time and under conditions to allow attachment of the molecule on the support; and decoupling the mold from the support.
  • a system to attach a molecule on a microfluidic support along a predetermined microfluidic pattern comprises: a mold comprising microfluidic channels, the microfluidic channels having an inlet and an outlet, the outlets of the channels configured to form part of the predetermined pattern, and a support suitable to be coupled with the mold.
  • the methods and systems for attaching a molecule on a support on a microfluidic support along a predetermined microfluidic pattern can be used to manufacture an array and/or a substrate according to the present disclosure, in embodiments wherein the pattern is composed of substantially parallel lines forming a barcoded pattern.
  • Arrays, substrates, devices, methods and systems herein disclosed provide information in a one-dimensional fashion which can be detected with a single line scan (line profile) perpendicular to the strip direction to complete reading all information. In this way, is possible to obtain all the necessary information without need of a precise move of a reader (e.g. a scan head) which is instead required in imaging 2D array of the art.
  • This feature can allow, in certain embodiments, the reading of barcode DNA array as easy as scanning the product barcode in supermarket.
  • Arrays, substrates, devices, methods and systems herein disclosed can provide an increased concentration of capture agents suitable to bind the target and, therefore, increased detection sensitivity (e.g. up to 0.1 picomolar) when compared to prior art techniques.
  • Arrays, substrates, devices, methods and systems herein disclosed can allow an increased number of locations for a specific capture agent on a surface (herein also indicated as spots). Accordingly, the arrays, devices methods and systems herein disclosed also allow detection of an increased number of targets or target related parameters (e.g. 50 targets or more) in comparison with the ones detectable with prior art techniques.
  • targets or target related parameters e.g. 50 targets or more
  • Arrays, substrates, devices, methods and systems herein disclosed are also compatible with microfluidic fabrication techniques, since the spots can be placed in positions that can be defined not only with respect to each other, but also with respect to microfluidic channels and/or other structure on the surface.
  • Arrays, substrates, devices, methods and systems herein disclosed allow providing high density capture agents on a substrate, with a decreased level of impurities in comparison to prior art techniques.
  • Arrays, substrates, devices, methods and systems herein disclosed also allow detection of a larger number of biomarkers in a reduced time (e.g. about 9 minutes) with respect prior art techniques, in particular in embodiments wherein the array is integrated with microfluidics.
  • Arrays, substrates, devices, methods and systems herein disclosed allow detection from a sample reduced in size (e.g. 500 nano liter per barcode and/or protein sections from only one cell) in comparison to the samples analyzed with prior art techniques, in particular in embodiments wherein the array is integrated with microfluidics
  • the arrays, substrates, devices, systems and methods herein disclosed allow detection of multiple biomarkers within the same environment, and in particular the same microfluidics environment, using a single assay technique, the relative error associated with measurements of different biomarkers from the same sample is minimized.
  • Suitable target molecules include, but are not limited to, proteins, peptide, polypeptide, ligands, metabolites, nucleic acid, polynucleotide, carbohydrate, amino acid, hormone, steroid, vitamin, drug, drug candidate, virus, bacteria, cells, microorganisms, fragments, portions, components, products, epitopes of virus, bacteria, microorganisms and/or cells, polysaccharides, lipids, lipopolysaccharides, glycoproteins, cell surface markers, receptors, immunoglobulins, albumin, hemoglobin, coagulation factors, volatile gas molecules, particles, metal ions and the antibodies to any of the above substrates.
  • the arrays, substrates, devices, methods and systems herein disclosed are applicable to performance of assays including diagnostic assays, environmental monitoring assays, heath/drug response monitoring assays and assays performed for research purposes.
  • assays including diagnostic assays, environmental monitoring assays, heath/drug response monitoring assays and assays performed for research purposes.
  • Exemplary assays that can be performed include but are not limited to detection of cancer biomarkers (e.g.
  • prostate cancer antigen PSA
  • human chorionic gonadotropin hCG
  • detection of liver toxicity biomarker C-reactive protein CRP
  • CRP liver toxicity biomarker C-reactive protein
  • C3 detection of immuno complement proteins like C3
  • detection of cytokines such as interferon gamma (IFN-gamma), tumor necrosis factor alpha (TNF-a), interleukin 1 alpha (IL-1 alpha), interleukin 1 beta (IL-1 beta), transforming growth factor beta (TGF beta), interleukin 6 (IL-6), interleukin 10 (IL-10), interleukin 12 (IL-12), granulocyte macrophage colony stimulating factor (GM-CSF) etc
  • detection of chemokines: CCL2 also called monocyte chemoattractive protein-1, MCP—1
  • demonstration of detection of complementary DNA molecules CCL2 (also called monocyte chemoattractive protein-1, MCP—1)
  • Additional applications of the arrays, substrates, devices, methods and systems herein disclosed include but are not limited to use the patterning technique to make a barcode array of gas selective polymers as gas sensors; patterning liquid crystal film for LCD, and assemble magnetic particle array using DNA-iron oxide nanoparticle conjugates (just like the antibody-DNA conjugates) for magnetic barcodes (product ID).
  • FIG. 1 shows a schematic representation of the method to manufacture a reversed or inversed phase barcoded array according to an embodiment herein disclosed.
  • Panel A shows a barcode pattern including a number of stripes or bars corresponding to immobilized serum molecules from various patients.
  • Panel B shows a barcode pattern wherein the bars are provided by microfluidic channels formed on top of the array of Panel A.
  • FIG. 2 shows a schematic representation of a method and equipment to detect a barcoded array according to an embodiment herein disclosed.
  • FIG. 3 shows a schematic representation of a comparative detection of a spot array and of a barcoded array according to an embodiment herein disclosed.
  • FIG. 4 shows a schematic representation of an exemplary passage in the pattering methods and systems for producing a barcoded array according to an embodiment herein disclosed.
  • FIG. 5 shows a schematic representation of the method to manufacture a patterned substrate, using a multi-layer fluidic channel device according to an embodiment herein disclosed.
  • FIG. 6 shows an exemplary array according to an embodiment herein disclosed.
  • FIG. 7 shows two images corresponding to an exemplary molecular detection using a 20 ⁇ m barcoded array (panel A) and a 2 ⁇ m barcoded array (panel B) according to an embodiment herein disclosed.
  • FIG. 8 shows a computer-aided design of the barcode array according to an embodiment herein disclosed and a related use.
  • the panel on the bottom shows thirteen different capture agents (A-M) flowed into a set of parallel fluidic channels each channel having a width of 20 ⁇ m.
  • the top panel is the enlarged view of a selected area.
  • FIG. 9 shows the execution of multiple assays in twelve isolated wells using a barcoded array according to an embodiment herein disclosed.
  • Panel A shows a barcoded array manufactured on a supporting glass slide.
  • Panel B shows protein detection from the array of Panel A visualized by fluorescence imaging.
  • FIG. 10 shows a schematic representation of the method to detect target molecules using a group of distinct capture agents that are directly patterned into a barcoded array according to an embodiment herein disclosed.
  • FIG. 11 shows a schematic representation of the method to detect target molecules using a group of distinct capture agents that are immobilized onto the specific location of a pre-determined barcoded array via a set of linkers according to an embodiment herein disclosed. This is exemplified by the detection of target antigen using captured antibodies encoded by a set of complementary DNA molecules.
  • FIG. 12 shows a schematic representation of the method to vary the loading of capture agents and consequently the sensitivity and concentration range for the detection of targets using a barcoded array according to an embodiment herein disclosed.
  • FIG. 13 shows a schematic representation of a method to manufacture a device including a barcoded array according to an embodiment herein disclosed and a related use.
  • FIG. 14 shows an exemplary detection of protein targets according to an embodiment herein disclosed.
  • FIG. 15 shows an exemplary protein detection using a barcoded array according to an embodiment herein disclosed and comparison with the protein detection using a conventional pin-spotted array.
  • FIG. 16 shows an exemplary detection of target polynucleotides according to an embodiment herein disclosed.
  • FIG. 17 shows an exemplary multiplexed detection of multiple protein targets in a sample using a barcoded array according to an embodiment herein disclosed.
  • FIG. 18 shows an exemplary detection of a protein target according to an embodiment herein disclosed.
  • FIG. 19 shows an exemplary detection of multiple targets in a sample using a barcoded array according to an embodiment herein disclosed, and its comparison to the conventional array.
  • FIG. 20 shows a schematic representation of a method and system to detect targets according to an embodiment herein disclosed.
  • FIG. 21 shows an exemplary detection of a target in a series of samples according to an embodiment herein disclosed.
  • FIG. 22 an exemplary detection of a protein target in a series of samples over a large concentration range according to an embodiment herein disclosed.
  • FIG. 23 shows an exemplary detection of a biological profile according to an embodiment herein disclosed.
  • FIG. 24 shows an exemplary detection of a target at different concentration ranges according to an embodiment herein disclosed.
  • FIG. 25 shows data concerning the exemplary detection of a biological profile of FIG. 20A .
  • FIG. 26 shows detection of a protein profiling in a time span according to an embodiment herein disclosed.
  • FIG. 27 shows an exemplary quantitative detection according to an embodiment herein disclosed.
  • FIG. 28 shows an exemplary elaboration of biological profiles detected according to the exemplary embodiment illustrated in FIG. 21(A) embodiment herein disclosed.
  • FIG. 29 shows an exemplary detection of target proteins in a drop of fresh human blood.
  • FIG. 30 shows an exemplary detection of a human plasma proteome according to an embodiment herein disclosed.
  • FIG. 31 shows a schematic representation of the method to manufacture a patterned substrate according to an embodiment herein disclosed.
  • Arrays, substrates, devices, methods and systems for detecting a target, and in particular, a plurality of target molecules in a sample are herein disclosed.
  • detect indicates the determination of the existence, presence or fact of a target or signal in a limited portion of space, including but not limited to a sample, a reaction mixture, a molecular complex and a substrate.
  • a detection is “quantitative” when it refers, relates to, or involves the measurement of quantity or amount of the target or signal (also referred as quantitation), which includes but is not limited to any analysis designed to determine the amounts or proportions of the target or signal.
  • a detection is “qualitative” when it refers, relates to, or involves identification of a quality or kind of the target or signal in terms of relative abundance to another target or signal, which is not quantified.
  • target or “target molecule” as used herein indicates an analyte of interest.
  • analyte refers to a substance, compound or component whose presence or absence in a sample has to be detected. Analytes include but are not limited to biomolecules and in particular biomarkers.
  • biomolecule indicates a substance compound or component associated to a biological environment including but not limited to sugars, amino acids, peptides proteins, oligonucleotides, polynucleotides, polypeptides, organic molecules, haptens, epitopes, biological cells, parts of biological cells, vitamins, hormones and the like.
  • biomarker indicates a biomolecule that is associated with a specific state of a biological environment including but not limited to a phase of cellular cycle, health and disease state. The presence, absence, reduction, upregulation of the biomarker is associated with and is indicative of a particular state.
  • exemplary biomarkers include breast cancer marker HER2, ovarian cancer marker CA125, and heart disease marker thrombin.
  • sample indicates a limited quantity of something that is indicative of a larger quantity of that something, including but not limited to fluids from a biological environment, specimen, cultures, tissues, commercial recombinant proteins, synthetic compounds or portions thereof.
  • arrays, substrates, methods and systems are herein disclosed for the detection of multiple, distinct targets, such as biomolecules, or a panel of biomarkers.
  • targets such as biomolecules, or a panel of biomarkers.
  • each target is detected in a particular location on a surface, and the collection of detected biomolecules forms a pattern, or a barcode.
  • the arrays, devices, methods and systems herein disclosed can apply to the detection of the biomarker panel within a micro fluidics environment.
  • substrates devices methods and systems herein disclosed a plurality of capture agents attached to a substrate.
  • capture agents as used herein indicate a molecule capable of specific binding with a predetermined binding.
  • exemplary capture agents include but are not limited to polynucleotides and proteins, and in particular antibodies.
  • nucleotide indicates an organic polymer composed of two or more monomers including nucleotides, nucleosides or analogs thereof.
  • nucleotide refers to any of several compounds that consist of a ribose or deoxyribose sugar, joined to a purine or pyrimidine base and to a phosphate group and that are the basic structural units of nucleic acids.
  • nucleoside refers to a compound (as guanosine or adenosine) that consists of a purine or pyrimidine base combined with deoxyribose or ribose and is found especially in nucleic acids.
  • nucleotide analog or “nucleoside analog” refers respectively to a nucleotide or nucleoside in which one or more individual atoms have been replaced with a different atom or a with a different functional group. Accordingly, the term polynucleotide includes nucleic acids of any length DNA RNA analogs and fragments thereof. A polynucleotide of three or more nucleotides is also called nucleotidic oligomers or oligonucleotide.
  • polypeptide indicates an organic polymer composed of two or more amino acid monomers and/or analogs thereof.
  • polypeptide includes amino acid polymers of any length including full length proteins and peptides, as well as analogs and fragments thereof. A polypeptide of three or more amino acids is also called a protein oligomer or oligopeptide.
  • amino acid refers to any of the twenty naturally occurring amino acids including synthetic amino acids with unnatural side chains and including both D and L optical isomers.
  • amino acid analog refers to an amino acid in which one or more individual atoms have been replaced, either with a different atom, isotope, or with a different functional group but is otherwise identical to its natural amino acid analog.
  • protein indicates a polypeptide with a particular secondary and tertiary structure that can participate in, but not limited to, interactions with other biomolecules including other proteins, DNA, RNA, lipids, metabolites, hormones, chemokines, and small molecules.
  • antibody refers to a protein that is produced by activated B cells after stimulation by an antigen and binds specifically to the antigen promoting an immune response in biological systems and that typically consists of four subunits including two heavy chains and two light chains.
  • the term antibody includes natural and synthetic antibodies, including but not limited to monoclonal antibodies, polyclonal antibodies or fragments thereof. Exemplary antibodies include IgA, IgD, IgG1, IgG2, IgG3, IgM and the like. Exemplary fragments include Fab Fv, Fab′ F(ab′)2 and the like.
  • a monoclonal antibody is an antibody that specifically binds to and is thereby defined as complementary to a single particular spatial and polar organization of another biomolecule which is termed an “epitope”.
  • a polyclonal antibody refers to a mixture of monoclonal antibodies with each monoclonal antibody binding to a different antigenic epitope.
  • Antibodies can be prepared by techniques that are well known in the art, such as immunization of a host and collection of sera (polyclonal) or by preparing continuous hybridoma cell lines and collecting the secreted protein (monoclonal).
  • the wording “specific” “specifically” or specificity” as used herein with reference to the binding of a molecule to another refers to the recognition, contact and formation of a stable complex between the molecule and the another, together with substantially less to no recognition, contact and formation of a stable complex between each of the molecule and the another with other molecules.
  • Exemplary specific bindings are antibody-antigen interaction, cellular receptor-ligand interactions, polynucleotide hybridization, enzyme substrate interactions etc.
  • the term “specific” as used herein with reference to a molecular component of a complex refers to the unique association of that component to the specific complex which the component is part of.
  • the term “specific” as used herein with reference to a sequence of a polynucleotide refers to the unique association of the sequence with a single polynucleotide which is the complementary sequence.
  • attach refers to connecting or uniting by a bond, link, force or tie in order to keep two or more components together, which encompasses either direct or indirect attachment such that for example where a first molecule is directly bound to a second molecule or material, and the embodiments wherein one or more intermediate molecules are disposed between the first molecule and the second molecule or material.
  • substrate indicates an underlying support or substratum.
  • exemplary substrates include solid substrates, such as glass plates, microtiter well plates, magnetic beads, silicon wafers and additional substrates identifiable by a skilled person upon reading of the present disclosure.
  • the capture agents used in the arrays, devices, methods and systems herein disclosed can be either directly deposited onto substrate to form an array or immobilized by linker molecules that are pre-deposited onto substrate and capable to specific binding to capture agent for form an array. Since they are functional to the attachment of capture agents to a substrate, linker molecules can be considered as capture agent components.
  • each capture agent can be bindingly distinguishable and/or positionally distinguishable from another.
  • bindingly distinguishable indicates molecules that are distinguishable based on their ability to specifically bind to, and are thereby defined as complementary to a specific molecule. Accordingly, a first molecule is bindingly distinguishable from a second molecule if the first molecule specifically binds and is thereby defined as complementary to a third molecule and the second molecule specifically binds and is thereby defined as complementary to a fourth molecule, with the fourth molecule distinct from the third molecule.
  • positionally distinguishable refers to with reference to molecules, indicates molecules that are distinguishable based on the point or area occupied by the molecules. Accordingly, positionally distinguishable capture agents are substrate polynucleotide that occupy different points or areas on the assaying channel and are thereby positionally distinguishable.
  • each capture agent of the plurality of capture agents is capable of specifically binding each target of the plurality of targets to form a capture agent target binding complex, and the plurality of capture agents arranged on the array so that capture agent target binding complexes are detectable along substantially parallel lines forming a barcoded pattern.
  • substrates systems and methods are herein disclosed wherein the substrate is configured to allow attachment of targets (herein also reverse barcode or inversed-phase barcode), and in particular detectable targets, along substantially parallel lines forming a barcoded pattern.
  • targets herein also reverse barcode or inversed-phase barcode
  • FIG. 1 An exemplary illustration of reverse barcode is illustrated in FIG. 1 , wherein a barcoded pattern including a number of bars corresponding to immobilized serum molecules from various patients and microfluidic channels for providing various drugs to be contacted with the serum of the patients for a bio-assay, are shown.
  • detection of the attached target and/or capture agent target complex is performed by providing a labeled molecule, which includes any molecule that can specifically bind a capture agent target complex to be detected (e.g. an antibody, aptamers, peptides etc) and a label that provides a labeling signal, the label compound attached to the molecule.
  • the labeled molecule is contacted with the attached target and/or capture agent target complex and the labeling signal from the label compound bound to attached target and/or the capture agent-target complex on the substrate can then be detected, according to procedure identifiable by a skilled upon reading of the present disclosure and, in particular, of the Examples section.
  • the signal readout that is used in the arrays, devices, methods and systems herein disclosed can be realized using labels such as probes that transduce the capture event of target molecule into optical, electrical or magnetic signal.
  • probes include, but not limited to, fluorescent dyes, gold nanoparticles, silver nanoparticles, semiconductor nanoparticles (e.g. CdSe, ZnSe and/or their core-shell nanoparticles), and iron oxide nanoparticles.
  • label and “labeled molecule” as used herein as a component of a complex or molecule refer to a molecule capable of detection, including but not limited to radioactive isotopes, fluorophores, chemoluminescent dyes, chromophores, enzymes, enzymes substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, nanoparticles, metal sols, ligands (such as biotin, avidin, streptavidin or haptens) and the like.
  • fluorophore refers to a substance or a portion thereof which is capable of exhibiting fluorescence in a detectable image.
  • labeling signal indicates the signal emitted from the label that allows detection of the label, including but not limited to radioactivity, fluorescence, chemolumiescence, production of a compound in outcome of an enzymatic reaction and the likes.
  • the labeled molecule can be formed of a plurality of labeled molecules.
  • Each labeled molecules comprises a molecule that specifically binds one target of the one or more targets/plurality of targets and a label compound attached to the molecule, the label compound providing a labeling signal, each labeled molecule detectably distinguishable from another.
  • detectably distinguishable indicates molecules that are distinguishable on the basis of the labeling signal provided by the label compound attached to the molecule.
  • Exemplary label compounds that can be use to provide detectably distinguishable labeled molecules include but are not limited to radioactive isotopes, fluorophores, chemoluminescent dyes, chromophores, enzymes, enzymes substrates, enzyme cofactors, enzyme inhibitors, dyes, metal ions, nanoparticles, metal sols, ligands (such as biotin, avidin, streptavidin or haptens) and additional compounds identifiable by a skilled person upon reading of the present disclosure.
  • bindingly distinguishable capture agents are used different analytes can be detected by use of detectably distinguishable labeled molecules each specific to a separate analyte of interest.
  • the detection method can be carried via fluorescent based readouts, in which the labeled antibody is labeled with fluorophore which includes but is not limited to small molecular dyes, protein chromophores and quantum dots.
  • on-chip detection can be performed with methods other than fluorescence based techniques. Exemplary suitable techniques include, calorimetric detection, enzyme-catalyzed production of different colored or fluorescent dyes (with different colors being associated with distinct analytes), microparticle/nanoparticle based detection using electron microscopy, AFM, or dark-field microscopy, magnetic detection using magnetic micro/nanoparticles, electrical detection methods.
  • detection can be performed by methods that use signal amplification such as gold nanoparticle based detection followed by gold or silver amplification.
  • detection can be carried out on gold nanoparticle-labeled secondary detection systems in which a common photographic development solution can amplify the gold nanoparticles as further described below. Also, if the readout comes from dark field scattering of gold particles, single molecule digital proteomics is enabled.
  • the detection can be performed with the aid of suitable equipments.
  • any equipment configured to read barcoded pattern can be used as long as the relevant sensitivity is applicable to the detection of choice.
  • reading the information of the arrays herein disclosed can be performed using a simple line-scan reader such as the laser line scanner schematically illustrated in FIG. 2 .
  • the one-dimensional layout of the arrays renders a higher reliability as compared to the conventional circular spot arrays as schematically illustrated in FIG. 3 .
  • FIG. 3 is shown how a scan reading from a same line scanner (scan b) provides a higher reliability for a barcoded pattern (panel B) if compared with a spotted array (Panel A).
  • Additional equipment suitable to detect the array herein described can be identified by a skilled person upon reading of the present disclosure.
  • laser microarray scanner such as. Axon Genepix 4000 series scanner, Affymetrix 300 scanner, etc
  • scanning laser confocal microscope e.g. Nikon Eclipse C1si microscope
  • the parallel-stripe pattern allows a single scan of laser to read out full information with high fidelity and reliability as illustrated in FIGS. 2 and 3 . This feature opens the possibility of implementing a simple laser line scanner similar as the barcode reader in supermarket for reading the barcode array described herein.
  • light scattering microscope such as Nikon® Eclipse LV100
  • electroless metal plating is used to enhance the nanoparticle signal
  • a flat bed scanner such as Nanosphere Verigene® reader
  • magnetic particles are used as probes
  • a magnetoresistive sensor similar to a scan head in a hard disk can be used to read out the barcode information.
  • Arrays and substrates herein disclosed can be manufactured using methods and systems to attach a material to a support along a predetermined pattern herein also disclosed (herein also indicated as patterning methods and systems).
  • the methods and systems to attach material can be used to manufacture arrays and substrate according to any predetermined pattern.
  • the methods and systems herein disclosed can be used to manufacture barcoded arrays and substrates.
  • the barcoded surface patterning can be performed as described below in the exemplary procedure illustrated with reference to microfluidics channels patterned from polydimethylsiloxane (PDMS) that are weakly or strongly bonded to glass substrates.
  • PDMS polydimethylsiloxane
  • the patterning method is not limited the specific microfluidic features and materials used and that a different number of channels with different dimensions as well other materials, such as injection molded micro fluidics channels, semiconductor wafers, etc., all identifiable by a skilled person upon reading of the present disclosure, may all be utilized.
  • a mold can be fabricated by molding a polymer such as a PDMS elastomer from a master template, to include microchannels each having an inlet and an outlet and each of the outlets is such that it forms a portion of the desired pattern (in particular a barcoded pattern).
  • the polymer is molded using photolithography to create a photoresist pattern on a silicon wafer. Those embodiments, allow a particularly rapid prototyping.
  • FIG. 4 An exemplary illustration of a mold fabrication for the patterning methods and systems herein disclosed is illustrated in FIG. 4 wherein fabrication of a PDMS microchannel stamp for flow patterning of a barcode array is disclosed.
  • the mold can be manufactured by providing a silicon “hard” master and by transferring the photolithographically-defined pattern into the underlying silicon wafer using a deep reactive ion etching (DRIE) process.
  • DRIE deep reactive ion etching
  • the molded polymer can then be coupled and in particular bonded onto a support, such as a glass surface, which provides the floor for the channels of barcoded pattern.
  • a support such as a glass surface
  • FIG. 5 An exemplary illustration of a design two-layer PDMS fluidic channel device used for creating a multiple ring pattern (bull's eye) on a glass slide is shown in FIG. 5 .
  • the substrate can be pre-coated with a material of interest.
  • a material of interest for example in embodiments wherein a barcode is manufacture using the DEAL technology further illustrate below, a polyamine polymer or poly-L-lysine polymer (Sigma-Aldrich), can be pre-coated prior to bonding to increase DNA loading of the final barcoded pattern (see below and in particular Example 2).
  • the number of microfluidic channels determines the size of the barcode array.
  • the barcoded array comprises 13 to 20 parallel microchannels that wind back and forth to cover a large area (3 cm ⁇ 2 cm) of the support with the DNA barcode microarray.
  • patterning can be performed by contacting the capture agent or molecule of choice on the support for a time and under conditions to allow attachment on the support. More particularly, in some embodiments patterning can be performed by providing solutions, each containing the molecule of choice (e.g. a different strand of primary DNA oligomers prepared in 1 ⁇ PBS buffer in embodiments wherein the array is coupled with DEAL technology), can be flowed into each of the microfluidic channels. Then, the solvent of the solution can be allowed to evaporate, e.g. by placing the solution-filled chip in a dessicator to allow solvent (e.g. water) to evaporate completely through the gas-permeable PDMS, leaving the molecules to be attached (e.g. DNA molecules) behind. In some embodiments, this process can take from several hours to overnight to complete.
  • solvent e.g. water
  • the mold is usually decoupled from the support.
  • the patterned molecule can be subjected to subsequent treatments (e.g. DNA molecule can be fixed to the glass surface by thermal treatment at 80 C for 4 hours, or by UV crosslinking; removal of salts or other precipitates that might have formed during one or more of the previous operations which can be removed, for example, by rapidly dipping the slide in deionized water prior to bonding the blood-assay chip to the slide).
  • subsequent treatments e.g. DNA molecule can be fixed to the glass surface by thermal treatment at 80 C for 4 hours, or by UV crosslinking; removal of salts or other precipitates that might have formed during one or more of the previous operations which can be removed, for example, by rapidly dipping the slide in deionized water prior to bonding the blood-assay chip to the slide.
  • a series of microfluidics channels is patterned into PDMS, and those channels bonded onto a glass surface so that one out of the 4 channel walls is the glass surface itself.
  • the numbers of micro fluidics channels determines the size of the barcoded array. In this way, a solution flowing through the micro fluidics channel will come into contact with the glass substrate.
  • Typical dimensions of these micro fluidics channels for barcoded used for biological assays are 10 micrometers or larger.
  • the channel width defines the width of an individual bio-assay measurement area within the final bar code. In those embodiments, if the final measurement of the biomolecule is done using optical methods, then a 10 micrometer wide area constitutes a size that is readily imaged using low-cost optics. Larger and smaller bars are also possible.
  • a different material and in particular a different biological species (or a different concentration of the same biological species), such as DNA oligomers, can then be flowed in to each of the individual micro fluidics channels.
  • the biological species or other patterned material can then be attached to the glass surface areas within those microfluidics channels using electrostatic or other chemical interactions.
  • the glass may be pre-coated with some molecular component to increase the chemical interaction between the biological species and the glass surface (see above and below in particular Example 2).
  • the solvent from the solution containing the patterned material is then removed. If that solution is water and the fluidics (e.g. microfluidics) is fabricated from PDMS, then the water can be let naturally evaporate through the PDMS, leaving the patterned material attached to the substrate thus providing a the patterned array on the substrate. In some embodiments, it may be desirable to introduce additional channel (e.g. micro fluidics channels) at this point for handling and introducing the biological sample of interest.
  • additional channel e.g. micro fluidics channels
  • the microfluidic bar-code patterning chip may be made by molding silicon elastomer from a master template.
  • the master template may be fabricated from many materials.
  • One method is to fabricate the master by using photolithography to expose an SU8 2015 photoresist. Regions of the photoresist are removed following lithographic exposure, and the remaining material constitutes the master.
  • photolithographic patterning methods coupled with deep reactive ion etching (DRIE) can be utilized to prepare a master from a silicon wafer.
  • DRIE deep reactive ion etching
  • the patterned material can comprise any substance of interest suitable to be attached to a support, including organic or inorganic substances, Exemplary inorganic material that can be patterned using the patterning methods and systems herein disclosed include but are not limited to gold nanoparticles that can attach to thiol functionalized substrate surface, iron oxide nanoparticles that can be deposited onto the substrate using magnetic field, and silica particles that can be immobilized by cationic polymer coated substrate, and so on.
  • Exemplary organic that can be patterned using the patterning methods and systems herein disclosed include but are not limited to living species and their mixtures such as cells, virus, bacteria and fungi, complex biospecimens and their mixtures such as tissue, tissue lysate, cell lysate, serum, saliva and joint fluid, monotypic molecule and their mixtures such as polynucleotides, proteins, antibodies, glycoproteins, polysaccharides, lipopolysaccharides, ligands, peptides, polypeptides, lipids, drugs, drug candidates, antigens and the fragments, portions, and components or any of above.
  • living species and their mixtures such as cells, virus, bacteria and fungi, complex biospecimens and their mixtures such as tissue, tissue lysate, cell lysate, serum, saliva and joint fluid, monotypic molecule and their mixtures such as polynucleotides, proteins, antibodies, glycoproteins, polysaccharides, lipopolysaccharides,
  • the organic materials can also include non-biological materials such as polymers, oligomers, dye molecules, conducting polymers, responsive polymer, gas sensing polymers, liquid crystals and metal organic frameworks (MOFs), carbon nanotube, fullerene, grapheme, and their nano/microstructures.
  • the patterned material comprises capture agents.
  • the patterned material comprises detectable targets.
  • the patterned material comprises a material, such as cells or other biological material to be assayed.
  • the patterned material can comprise other organic or inorganic substance for which the barcoded configuration is desired (e.g. liquid crystal for LCD manufacturing, or gas selective polymers to be used as gas sensors).
  • a pattern and in particular a barcoded pattern or array can be created on very small area and patterning of magnetic ID or other material can therefore be performed onto small-sized products.
  • the capture agent is formed by a polynucleotide and in particular a DNA polynucleotide, that bind about 10 to 20 consecutive bases of a target RNA via complementary hybridization.
  • the arrays, substrates, methods and systems herein disclosed can be used to detect messenger RNA (mRNA) and in particular mRNA from a biospecimen (e.g. tissue lysate).
  • mRNA messenger RNA
  • another labeled DNA stand e.g. fluorescently labeled
  • a multiplexed measurement of a panel of mRNA molecules can be performed on a barcode array patterned with stripes of their capture agent DNA.
  • the target is a microRNA (miRNA) a type of short RNA molecules (22 bases) that regulate gene expression at the post-transcription level
  • the target can be a transcription factor
  • the capture agent is a polynucleotide and in particular a DNA polynucleotide having the same sequence of the binding site of the transcription factor, or a portion thereof or an homologous sequence thereof.
  • fluorescence-labeled or biotin-labeled antibodies are then used for signal readout.
  • the lines are formed by one or more channels configured to host the material to be patterned.
  • the fluidic channel width can be made ranging from 0.5 ⁇ m to 1 cm.
  • the height can be typically > 1/10 of the channel width when a soft materials such as PDMS is employed, and can be less if a harder material (e.g. glass, silicon, polystyrene, PMMA, polycarbonate or epoxy) is used to make the fluidic channels.
  • the channel can be as short as 1 mm and up to meters when the channel is shaped to cover the entire substrate (e.g. a glass slide 1′′ ⁇ 3′′) for example by turning back and forth on the substrate.
  • the channel length can be longer since the length is defined by the substrate and the application of interest.
  • the array can be in principle made into any custom-designed shapes such as stripes, rings, concentric rings (see for example the illustration of FIGS. 5 and 6 ), triangles, rectangles, polyhedrons, stars, cross-bars, letters, pictures on flat, convex, concaved or irregular substrates.
  • a multiple ring pattern suitable to application such as a bio-assay for detection of targets secreted by a sample such as a cell placed in the middle, is shown.
  • the images of FIG. 6 show the detection of proteins IL-2 and TNF- ⁇ visualized by Cy3 and Cy5 fluorescent probes.
  • the channels width can be anywhere from 0.5 ⁇ m to 1 cm and the height can range from 1 ⁇ m to 1 cm, and the length can any that is allowed by the area of the given substrate.
  • An exemplary 2- ⁇ m barcode array is shown in FIG. 7 , wherein a barcoded array of fluorescent DNA molecules manufactured according to the teaching of the present disclosure, is illustrated.
  • a channel width of 20 ⁇ m and height of 20 ⁇ m are preferred when a 200- ⁇ M capture DNA solution is used and the developed array is visualized using fluorescence scanner.
  • a DNA barcoded array is used to immobilize DNA encoded antibodies and subsequent immuno-sandwich assay, the same channel width and height are preferred (see below description of DEAL technology).
  • some or all of the substantially parallel lines are connected to one another through at least one of the ends. More particularly, in applications wherein the lines are formed by channels the substantially parallel lines can be connected to one another to form a single channels configured in a serpentine-like shape. Serpentine-like channels allow the fabrication of repeated barcode arrays over a large area, e.g. the entire glass slide (1′′ ⁇ 3′′), in a single step of flowing capture agents. It represents a significant advantage in large-scale, low cost manufacture of barcoded arrays for detection applications. In addition, it allows an assay to be executed in multiple repeats at the same thus reduce the statistic errors. An exemplary illustration of a serpentine-like channel is shown in FIG. 8 . Additional connections between the substantially parallel lines of a pattern or multiple patterns (for example multiple barcoded patterns connected to form a pyramid to increase DNA loading in application wherein barcode is manufactured in connection with DEAL technology).
  • the material to be patterned can be disposed along the parallel lines according to a specific experimental design of choice.
  • the capture agents can be disposed with each capture agent disposed along one line, or with two or more capture agents located disposed along portions of a single channel.
  • the material to be tested (and in particular detected) can be patterned along one line or portion of a line of the barcode. Exemplary illustrations of those embodiments are shown in FIGS. 1 and 7 .
  • the patterned material can be used for target detection.
  • typically capture agents are patterned on the substrate, to form detectable capture agent target complexes.
  • detectable targets are patterned directly on the material.
  • a number of serum samples from multiple patients can be patterned into a barcoded array. In such array, each stripe contains the biomolecules in the entire plasma proteome of that patient. This array can be exploited to screen for antibodies, ligands, drug candidates, and comparison of biological profiles among patients.
  • Those embodiments are exemplified for the barcoded arrays, substrates, methods and systems of Examples 3-14 and illustrated in the related figures and further described below.
  • assays are performed in a non-microfluidic environment.
  • An exemplary illustration of those embodiments is shown in FIG. 9 , wherein execution of multiple assays in twelve isolated wells using a barcoded array is illustrated.
  • the barcoded array illustrated in FIG. 9 is manufactured on a supporting glass slide including wells, wherein. each well contains a different sample such as human serum.
  • protein detection from the different samples is visualized by fluorescence imaging.
  • assays are performed in microfluidics which allows handling particularly small amounts of biospecimens (such as a finger prick of blood, tissue from skinny needle biopsy, etc).
  • the barcode array can be used to detect multiple proteins and/or genes from a single cell via on-chip single cell culture, lysis, mRNA and protein isolation/purification, in particular using an integrated microfluidic device such as the one described in the U.S. Application entitled “Microfluidic Devices, Methods and Systems for Detecting Target Molecules” Serial No. to be assigned filed on Jul. 16, 2008, Docket Number P235-US, incorporated herein by reference in its entirety.
  • microfluidic applications wherein the sample is a material of biological origin (bio sample) and the targets are biomarkers.
  • bio sample a material of biological origin
  • biomarkers biomarkers
  • the arrays, devices methods and systems herein disclosed can be used to perform a surface bound bioassay based on detection a biomolecule of interest in some biomaterial, such as blood, serum, biological tissue, or as a component of a cell culture (herein also indicated as bio-barcode assay).
  • the biological material can be pretreated so as to release the biomolecules of interest, to remove biological material that can interfere with binding of the biomolecules in the surface bound bioassay.
  • An exemplary pretreatment procedure includes separating blood cells from blood plasma (or serum), and then measuring the proteins from the plasma. In other procedures the separated cells could be further separated into white and red blood cells, which can be therefore subjected to further analysis.
  • An exemplary surface bound bioassay can be carried out as follows: The biomolecule of interest is bound to a (primary or 1°) surface-bound capture agent molecule (e.g. an antibody or complementary single-stranded DNA oligomer) that specifically recognizes and binds to the biomolecule of interest. Typically, a secondary (or 2°) capture agent containing some label for detection, such as a fluorescent molecule, is introduced to bind to the surface-bound biomolecule.
  • a secondary (or 2°) capture agent molecule e.g. an antibody or complementary single-stranded DNA oligomer
  • the bio-barcode can be manufactured patterning the capture agents of choice on a substrate along substantially parallel lines. In certain microfluidic applications the substantially parallel lines can be formed by channels or channel portions. Exemplary illustration of different embodiments wherein capture agents are attached to a surface in a bio-barcode are shown in FIG. 10 (capture agents DNA molecules for detection of polynucleotide (e.g. mRNA and microRNA) to be configured in a barcoded array), FIG. 11 (DNA-encoding antibodies to enable immuno-sandwich assay on barcode array allowing detection of proteins, cell surface markers, glycoproteins, virus and bacteria in multiplex) and FIG. 12 (schematic illustration showing how increased DNA loading helps to enhance detection sensitivity in application wherein the bio-barcode is coupled with DEAL technology see below).
  • FIG. 10 capture agents DNA molecules for detection of polynucleotide (e.g. mRNA and microRNA) to be configured in a barcoded array
  • FIG. 11 DNA-encoding antibodies to enable immuno-sandwich as
  • Patterning of capture agents results in an increased sensitivity of molecules such as polynucleotide, nucleic acid (mRNA, miRNA, DNA etc).
  • An increased sensitivity could be in particular associated with two factors: (1) the increased loading of capture DNA using poly-amine to coat substrate surface (for embodiments wherein the capture agent is a polynucleotide and in particular DNA) and (2) the reduced feature size with respect to conventional pin spotted arrays (e.g. 20 ⁇ m in barcoded array vs. 200 ⁇ m in conventional pin-spotted array) lowers the diffusion barrier and leads to high binding efficiency.
  • the capture agents include one or more component.
  • the capture agents can be formed by a substrate polynucleotide and a polynucleotide encoded-protein in application of the technology (herein also identified as DEAL) described in U.S. patent application Ser. No. 11/888,502 herein incorporated by reference in its entirety.
  • substrate polynucleotide refers to a polynucleotide that is attached to a substrate so to maintain the ability to bind to its complementary polynucleotide.
  • a substrate polynucleotide can be in particular comprised of a sequence that specifically binds and is thereby defined as complementary with an encoding-polynucleotide of a polynucleotide encoded protein.
  • polynucleotide-encoded protein refers to a polynucleotide-protein complex comprising a protein component that specifically binds to, and is thereby defined as complementary to, a target and an encoding polynucleotide attached to the protein component.
  • the encoding polynucleotide attached to the protein is protein-specific.
  • Those embodiments can be used to perform assays that exploit the protein-specific interaction to detect other proteins, cytokines, chemokines, small molecules, DNA, RNA, lipids, etc., whenever a target is known, and sensitive detection of that target is required.
  • polynucleotide-encoded antibody refers to a polynucleotide-encoded protein wherein the protein component is an antibody.
  • each protein specifically binds to, and is thereby defined as complementary to, a pre-determined target, and each encoding polynucleotide-specifically binds to, and is thereby defined as complementary to, a pre-determined substrate polynucleotide.
  • the protein-target interaction is an antibody-antigen interaction.
  • the interaction can be receptor-ligand, enzyme-substrate and additional protein-protein interactions identifiable by a skilled person upon reading of the present disclosure.
  • the protein-target interaction is a receptor-ligand interaction, where the receptor is streptavidin and the ligand is biotin, free or attached to any biomolecules.
  • An exemplary schematic illustration is shown in FIG. 12 .
  • the amount of polynucleotides that is deposited onto a given spatial location within the bio-barcode array can be controlled in view of the desired sensitivity and concentration range over which the biomolecule of interest can be detected.
  • concentration range over which that protein can be detected can be dramatically increased.
  • the concentration range of DNA detectable with a Bio-Barcode array coupled with DEAL can be as low as 1 pM to 100 nM using 200 ⁇ M loading of capture DNA on 20 ⁇ m barcode stripes.
  • Target molecules suitable for this technique include messenger RNAs, micro RNAs, the fragments of genomic DNAs, viral DNA, bacterial DNA, and synthesized polynucleotides.
  • Bio-Barcode is coupled with DEAL shows an increased sensitivity if compared with embodiments wherein protein capture agents are patterned directly on a substrate.
  • protein capture agents are patterned directly on a substrate.
  • all the target molecules that can be detected by DEAL are in principle detectable, but a lower sensitivity might be seen due to the poor stability of the antibody in a dry state.
  • the bio-barcode array When coupled with the DEAL technique, the bio-barcode array withstands the processing conditions associated with micro fluidics chip fabrication. As a consequence, the Bio Bar .Bar Code array can be advantageously manufactured as illustrated in the exemplary procedure outlined below with reference to an exemplary array including 10 antibodies used as capture agents (10 CAs) labeled with single stranded DNA used as encoding polynucleotide.
  • the 10 antibodies against the biomarker of interest are chemically labeled with single-stranded DNA (ssDNA) oligomers.
  • the complementary ssDNA′ oligomers can be deposited onto regions of a surface. DNA hybridization assembles the 10 CAs onto those particular regions.
  • the 10 CAs are patterned using microfluidics channels.
  • the channel widths and densities are limited by what can be patterned—smaller channels and higher densities than are practical using other methods are readily achieved.
  • channels of widths of at least 10 micrometers, spaced by distances of at least 50 micrometers, are most practical for typical bioassays, such as analyzing multiple proteins from serum. This allows for large numbers of measurements to be carried out in a relatively small microfluidics channel.
  • Spot sizes significantly smaller than 10 micrometers are also possible with this technique, as are significantly higher spot densities. These may be useful for more specialized applications, such as would be required for measuring a panel of protein biomarkers and other biomolecules from circulating tumor cells, cancer stem cells, and other extremely rare cell types.
  • bio-barcode patterned microfluidics channels are readily aligned with other microfluidics channels, such as are used for the handling of the biological specimen from which the assays are performed.
  • alignment markers that are utilized to align the bio-barcode micro fluidics channels can also be utilized to assemble the microfluidics channels for handling the biological sample. This is standard fabrication practice.
  • the density of 1° CAs that can be deposited onto such a small spot can be significantly higher than what can be achieved using spotting methods.
  • Repeated depositions of 10 CAs through the same microfluidics channels can achieve a very high surface loading of the 10 CAs.
  • the DEAL technique utilizes single-stranded DNA (ssDNA) oligomers as capture agents for the 10 CA antibodies that are, in turn, utilized to detect proteins.
  • the DNA can be loaded at very high levels using the bio-barcode Array because of the high solubility of DNA in water. This, in turn, can lead to very high coverage of the 1° antibody CAs.
  • Multiple numbers and classes of capture agents can be placed on specific, microscopic locations on a surface using microfluidic patterning of the 10 capture agents.
  • the panel of biomolecules is detected by detecting labeling signals (for example, fluorescence) from the region of the surface where the pattern of 10 capture agents was placed.
  • the capture agents can be attached on the location with a method to attach molecule along a predetermined pattern herein disclosed.
  • a barcode arrays can be manufactured that are at least an order of magnitude denser than conventional microarrays.
  • this result can be accomplished by creating a mold, e.g. a polydimethylsiloxane (PDMS) mold containing the desired number of microfluidic channels, e.g. 13-20 parallel microfluidic channels, with each channel conveying a different biomolecule capture agent.
  • PDMS polydimethylsiloxane
  • the barcoded array is a DEAL barcoded array.
  • poly-amine coated glass surfaces can be use to allow significantly higher DNA loading than do more traditional aminated surfaces.
  • DNA “bars” of 2 micrometers in width could be successfully patterned.
  • an about 20-micrometer ( ⁇ m) channel width was chosen because the fluorescence microarray scanner has a resolution of 5 ⁇ m.
  • a 10-fold increase in array density is achieved as compared to a typical pin-spotted DNA array (i.e. 150 ⁇ m spot diameters at 300 ⁇ m pitch), and greatly expands the numbers of proteins that can be measured within a microfluidic chip disclosed herein for a given sample size.
  • simultaneous detection of 12 to 20, up to 50 or even more than 50 proteins can be used in applications where detection of multiple targets is desired, for example detection of a biological profiles but also a variety of waste gases (e.g. from car engine exhaustion) or pollutes in a sample.
  • the protein assay can be carried out on the 10 CAs array as described above.
  • Use of DNA hybridization as an assembly strategy allows for multiple proteins to be detected within the same microenvironment, since the various 10 CA antibodies for the various proteins to be detected can be each labeled with a different ssDNA oligomer.
  • use of DNA hybridization as an assembly strategy allows preparation of the substrate including ssDNA in early in the fabrication process so that a substrate including the ssDNA can be treated, dried out, heated, shipped and provided to the final user in a ready to use systems that also include complementary capture agents. Exemplary applications are described in Examples 1 to 7 and in the related figures describe the bar-code array patterning technique and DEAL bar-code chips for protein detection.
  • the array herein disclosed can include patterning a variety of biological materials, e.g. DNA, proteins, sera and tissue lysates, using micro fluidic channels.
  • the Bio Bar-code Array method can be applied to the fabrication of bio-chips and integrated biosensing devices for high-density, multiplexed and sensitive detection of DNA and proteins in clinic diagnostics of human diseases like cancers, and for high-throughput drug screening.
  • the patterning is based upon a new, yet simple and reliable approach—micro channel guided surface patterning of a large number of different biological species to fabricate a small-size, high-density array.
  • microarray includes any one, two or three dimensional arrangement of addressable regions bearing a particular molecule associated to that region.
  • characteristic feature size for microarrays is micrometers.
  • kits of parts various components can be comprised in the kit independently.
  • a patterned substrate can be provided together with a label and/or other reagents suitable to perform detection.
  • a device suitable for detecting the pattern can also be included.
  • a system can include polynucleotide-encoded proteins and a patterned substrate comprised in the kit independently.
  • Molecules comprised in the kit e.g. the polynucleotide-encoded protein
  • the substrate provided in the system can have substrate polynucleotides attached thereto or other molecule attached according to the desired pattern.
  • the substrate polynucleotides, or the material to be patterned can be further provided as an additional component of the kit. Additional components can include labeled polynucleotides, labeled antibodies, labels, microfluidic chip, reference standards, and additional components identifiable by a skilled person upon reading of the present disclosure.
  • the components of the kit can be provided, with suitable instructions and other necessary reagents, in order to perform the methods here disclosed.
  • the kit will normally contain the compositions in separate containers.
  • kit for example written or audio instructions, on paper or electronic support such as tapes or CD-ROMs, for carrying out the assay, will usually be included in the kit.
  • the kit can also contain, depending on the particular method used, other packaged reagents and materials (i.e. wash buffers and the like).
  • the patterned material can be used for magnetic identity (ID) of small-sized products, which can include but are not limited to products carrying a biological material.
  • ID magnetic identity
  • small-sized products can include but are not limited to products carrying a biological material.
  • a magnetic ID bar has been widely used in tracking a product.
  • conventional magnetic ID pad is too large to be used for a small-sized subject such as a small camera CMOS chip, a fine jewel and a tiny artifact.
  • a Barcoded chip was fabricated according to the procedure schematically illustrated in FIG. 13 Panel A.
  • a silicon elastomer (PDMS) stamp was molded from a lithographically patterned silicon master. Then it was thermally bonded onto a poly-amine coated glass slide on which different biomolecule solutions are flowed into the parallel microchannels. Once the solutions evaporate completely, the PDMS stamp is peeled off and the glass side will be baked to create a robust Bio-Bar-code array.
  • the bar-code stripes can be made 2-20 ⁇ m in width and spacing, leading to increased array density compare to conventional microarrays. In principle, there is no limit for the number of primary molecules like DNA that can be patterned using this technique. It indeed enables the fabrication of a large-scale, high-density biomolecule array for systems biology and disease diagnostics.
  • the PDMS mold was bonded to a polylysine-coated glass slide via thermal treatment at 80° C. for 2 hours.
  • the polyamine surfaces permit significantly higher DNA loading than do more traditional aminated surfaces.
  • DNA “bars” of 2 micrometers in width have been successfully patterned using this technique.
  • a 20-micrometer ( ⁇ m) channel width was chosen because the fluorescence microarray scanner used by applications has a resolution of 5 ⁇ m.
  • the array so created was used in a bio assay as illustrated in FIG. 13 Panel B.
  • An integrated microfluidic device was placed onto the bio-bar-code chip microfluidic channels. There was no need of fine alignment to integrate the bio-bar-code pattern with the microfluidic systems. Different samples such as patient sera, tissue lysates can be assayed in each microfluidic channels, respectively.
  • the array depicted in FIG. 13 panel B enables high-through biodetection with minimum sample consumption.
  • FIG. 8 shows a schematic illustration of a mask design of a 13-channel patterning chip, wherein the letter A-M indicate the channels for flowing different DNA molecules. Additional modifications include subjecting the array to poly-amine surface modification, e.g. with the procedure exemplified in Example 2 below, to allow increased DNA loading. This modification leads to higher sensitivity and broader dynamic range as illustrate in the exemplary procedure of Example 3 below.
  • the glass surface was modified by treatment with poly-L-lysine (a poly-amine), yielding a three-dimensional matrix for DNA adsorption and markedly increasing the amount of DNA loading
  • FIG. 14 shows the effects of poly-lysine coating on an assay performed with DEAL technology. More particularly, FIG. 14 shows detection of protein targets using the barcoded array manufactured with low and high loading of primary DNA molecules and the resulting difference in the protein detection. As shown in the schematic illustration of panel (a) polylysine coating of the PDMS support results in an increased loading of DNA oligomer codes.
  • the DNA-loading density is estimated to be 6 ⁇ 10 13 molecules/cm 2 in our experiments, an order of magnitude higher than typical loading densities on amino-silane coated glass slides.
  • the protein detection sensitivity was improved by an order of magnitude, and the dynamic range was increased to 4 orders of magnitude, as compared with 2-3 orders of magnitude for the small-molecule amine (i.e. amino-propyl-triethoxyl silane, APTES) functionalized glass surface.
  • APTES amino-propyl-triethoxyl silane
  • a side-by-side comparison study was performed by running DEAL assays on three cytokines under identical conditions.
  • a glass slide was patterned with DNA oligomers A, B, C and a blank control O. Each bar was 20 ⁇ m in width.
  • the DNA solutions were all 50-100 ⁇ M.
  • the pin-spotted array was printed at the Institute for Systems Biology at 100 ⁇ M concentration. The typical spot size was 150-200 ⁇ m. Six sets of spots were printed corresponding to oligomers A, B, C, D, E, and F. Poly-l-lysine coated slides were used for both types of arrays.
  • the capture antibodies were conjugated to DNA oligomer codes as follows: A′ to IFN- ⁇ , B′ to TNF- and C′ to IL-2. Protein standards were diluted in 1% BSA/PBS solution at concentrations ranging from 1 fM to 1 nM. The incubation time for each step (blocking, conjugate hybridization, sample binding, detection-antibody binding, and fluorescent-molecule binding) was 30 min. The bar width was 20 ⁇ m.
  • FIG. 15 The results are illustrated in FIG. 15 wherein immunoassays run on DEAL barcode arrays is shown.
  • the bar-code array has a sequence of ABCOABCOABCOA (herein, “0” denotes that no 1° DNA was flowed in such microchannel). This data show proteins can be detected at concentration as low as 1 pM. Concentration dependence is indicated by the diagram of Panel (b) where quantitation of fluorescence intensity is plotted versus TNF- ⁇ concentration.
  • the line profile for the results obtained with 1-pM protein sample as indicated in Panel (a), is shown in the diagrams of Panel (c).
  • the sensitivity obtained in ELISA assays is projected to be ⁇ 10 pg/mL (0.8 pM) for TNF- ⁇ . Therefore, those experiments show that the DEAL barcode array combines ELISA-like sensitivity with a high degree of multiplexing for protein measurements.
  • the TNF- ⁇ detection sensitivity of the DEAL barcode arrays was higher and the projected sensitivity limit was better than 1 pM, as compared to 10-100 pM for conventional microarrays as illustrated in the comparative assay performed under the same condition using a conventional pin-spotting method of Panel (d) further illustrated in the comparative Example 6 below.
  • a barcoded array was used in a bio assay for detection of DNA.
  • a polynucleotide DNA
  • the results illustrated in FIG. 16 show that the patterned DNA oligomers exhibit a high affinity for binding their complementary strands.
  • FIG. 16 panel A fluorescence images are reported taken before and after hybridization of an A′ strand to its Alexa 532 labeled complementary stand.
  • Three different strands of DNA oligomers, nonfluorescent A, Alexa 532 labeled B (red) and Alexa 635 labeled (dark green) were flow-patterned on a polyL-lysine slide to form this bar-code chip. “0” denotes a non-patterned channel for bland control.
  • FIG. 16 Panel B The line profile of fluorescence intensity across the whole set of bar-code array is shown in FIG. 16 Panel B.
  • A′ is the target polynucleotide that was added into sample b and detected by fluorescence change in the location indicated by an asterisk.
  • a barcoded array assembled as disclosed herein was used for protein detection according to an experimental approach developed by the applicants.
  • the reference marks (DNA strand M) were visualized in all lanes with fluorescent green Cy3-M′ DNA molecules.
  • the 12 proteins showed a negligible extent of cross-talk.
  • assays were performed on serial dilutions of all 12 proteins on the DEAL barcode chip in view of the limitation imposed by the particular devices used, each allowing a maximum of 12 parallel assays to be executed.
  • 6 lanes were used for cross-talk validation and 6 lanes were used for dynamic range studies.
  • FIG. 17 shows cross-reactivity check and dilution curves for all 12 proteins.
  • the DEAL barcode images and line profiles from a single device of panel (a) show minimal cross-talk and a series of standard antigens ranging from 1 nM to 1 pM for all 12 proteins.
  • 2 proteins were combined in each assay lane ( FIG. 17 panel (a)).
  • the TGF-b antibody pair has a relatively lower binding affinity and a poorer detection limit in ELISA (according to the spec sheet, it is ⁇ 70 pg/mL compared to 5-10 pg/mL for most other cytokines). Predictably, this gave rise to a poorer performance in the DEAL assay. Although these curves clearly show a dynamic response of DEAL signals with respect to antigen concentrations, the variation remains pretty large as compared to bulk-scale immuno-assay such as ELISA.
  • Detection probes are not limited to fluorescent dyes, but can be any others that are capable to transduce signal from captured targets to optical, magnetic or electrical read out.
  • an alternative method of detection is provided by use of gold nanoparticles as probes.
  • An exemplary illustration of detection performed using gold nanoparticles is shown in FIG. 18 , wherein detection of target protein IL-1 ⁇ using gold nanoparticles as the probe is shown.
  • 40-nm gold nanoparticles were used to visualize the captured protein (e.g. IL-1 ⁇ ) of interest from human serum).
  • Example 3 A side-by-side comparison study was performed by running DEAL assays on three cytokines under identical conditions on a barcoded and a pin spotted microarrays under the experimental conditions illustrated in Example 3.
  • the pin-spotted array was printed at the Institute for Systems Biology at 100 ⁇ M concentration.
  • the typical spot size was 150-200 ⁇ m.
  • Six sets of spots were printed corresponding to oligomers A, B, C, D, E, and F. Poly-l-lysine coated slides were used for both types of arrays. Further details are illustrated in Example 3.
  • the only difference between the barcoded and conventional pin-spotted platforms used in the experiment shown in FIG. 15 is the feature size.
  • the barcode array has a line-width of 20 ⁇ m, whereas the spot size in conventional arrays is more than 150 ⁇ m.
  • the mechanism for improved sensitivity in the DEAL barcode assay is not completely understood. A possible explanation which is not intended to be limited is that the improved sensitivity could be attributed to a reduced kinetic barrier and decreased diffusion time.
  • FIG. 19 shows the use of DEAL bar-code immunoassay for the detection of five different proteins. The proteins are detected within an area that is less than would be required for the detection of a single protein using a conventional spotted microarray.
  • FIG. 19 show in particular multiple proteins simultaneously detected using a DEAL bio-barcode.
  • Panel A shows a schematic illustration of DEAL bar-code array for co-detection of a variety of proteins at the same time, including cytokines, chemokines, growth factors, intracellular signaling molecules and cancer markers.
  • Panel B shows a multiparameter DEAL Bar-code immunoassays of 5 proteins at the same time, detected from human reference serum that was spiked with the five proteins: hCG, TNF- ⁇ , IL-2, IL-a, and IL-1 ⁇ .
  • bar-code array can provide high density assay of a much greater number of protein s simply by increasing the number of microchannel s used in flow patterning.
  • FIG. 20 shows the microfluidic device used in patient serum measurement
  • FIG. 20 panel A shows. the schematic of the operation of a microfluidic device that is bonded onto a barcode array glass slide.
  • FIG. 20 Panel B shows a schematic illustrating the method to introduce fluid into microfluidic devices for molecular detection and in particular interfacing the outside sample loading/injection systems to the microfluidic device using plastic tubing and metal pins.
  • FIG. 21 illustrates the increased dynamic range of a barcoded array when it is utilized with DEAL technology.
  • the data show measurements of hCG, a pregnancy test marker, in human serum using the DEAL bar-code immunoassay that can cover the huge dynamic range >4 orders of magnitude.
  • results illustrated in FIG. 21 show that an expanded range of concentrations that can be detected from a single DEAL-based bio-barcode, demonstrated here for the detection of hCG.
  • hCG is a pregnancy test marker, as well as a serum cancer marker.
  • a single set of bar-code can distinguish the hCG concentration spanning from 25000 mIU/mL to O.25 mIU/mL (not shown) in a single step.
  • hCG human chorionic gonadotropin
  • NCI National Cancer Institute
  • FIG. 22 illustrates measurement of human chorionic gonadotropin (hCG) spiked in sera using a microfluidic DEAL barcode chip on an integrated platform including a barcoded array manufactured as described in U.S. Application entitled “Microfluidic Devices, Methods and Systems for Detecting Target Molecules” Serial No. to be assigned filed on Jul. 16, 2008, Docket Number P235-US herein incorporated by reference in its entirety.
  • hCG human chorionic gonadotropin
  • hCG level is tracked during pregnancy, with concentrations in the blood increasing from ⁇ 5 mIU/mL in the first week of pregnancy to ⁇ 2 ⁇ 10 5 mIU/mL in ten weeks.
  • concentrations in the blood increasing from ⁇ 5 mIU/mL in the first week of pregnancy to ⁇ 2 ⁇ 10 5 mIU/mL in ten weeks.
  • the microfluidic barcoded arrays used in the experiments herein described can accurately cover such a broad physiological hCG range.
  • FIG. 23 shows the use of an integrated microfluidic DEAL barcoded device for human serum protein profiling.
  • the serum samples from 12 cancer patients were measured in such prototype clinic test platform.
  • the protein profile obtained from this experiment exhibits unique patterns for individual patients, suggesting the efficacy of DEAL bar-code assay for serum-based cancer diagnosis and personalized medicine. This result displays a great indication for using a barcoded device and in particular an integrated DEAL barcode device for diagnostics and in particular human disease diagnostics.
  • Panel A illustrates the design of the integrated microfluidic device that can conduct a dozen of serum assays at the same time in a highly automated fashion.
  • Blue denotes the microfluidic channels for delivery of all reagents and samples.
  • Magenta shows the control channel for pressure-actuated valves where they intersect the microfluidic channels.
  • Overlay is a representative image of DEAL bar-code chip visualized by Cy5 fluorescence probes.
  • Panel B Measurement of 12 proteins out of 11 cancer patient serum samples and reference serum is illustrated in Panel B.
  • the number denotes each individual lanes used for protein detection out of a patient sample.
  • panel D A chart listing the specification and medical history of cancer patients is shown in panel D. Several unique signatures can be seen by comparing the medical record and the serum protein profile measured from DEAL bar-code assay.
  • the stored serum samples from 11 breast cancer patients (all female) and 11 prostate cancer patients (all male) were acquired from Asterand. Two unknowns were acquired from Sigma-Aldrich. Nineteen out of 22 patients were Caucasian and the remaining three were Asian, Hispanic and African-American. The medical history is summarized in the supplementary materials.
  • Finger pricks were performed using BD Microtainer Contact-Activated Lancets. Blood was collected with SAFE-T-FILL capillary blood collection tubes (RAM Scientific), which we pre-filled with 80 ⁇ L of 25 mM EDTA solution. A 10 ⁇ L volume of fresh human blood from a healthy volunteer was collected in this EDTA-coated capillary, dispensed into the tube, and rapidly mixed by inverting a few times. The spiked blood sample was prepared in a similar means except that 40 ⁇ L of 25 mM EDTA solution and 40 ⁇ L of recombinant solution were mixed and pre-added in the collection tube. Then 2 ⁇ L of 0.5 M EDTA was added to bring the total EDTA concentration up to 25 mM.
  • the integrated platforms were first blocked with the buffer solution for 30-60 minutes.
  • the buffer solution prepared was 1% w/v Bovine Serum Albumin Fraction V (Sigma) in 150 mM 1 ⁇ PBS without calcium/magnesium salts (Irvine Scientific).
  • DNA-antibody conjugates ( ⁇ 50-100 nM) were flowed through the plasma assay channels for ⁇ 30-45 min. This step transformed the DNA arrays into capture-antibody arrays. Unbound conjugates were washed off by flowing buffer solution through the channels.
  • the integrated platform was ready for the blood test. Two blood samples prepared as mentioned above were flowed into the integrated platforms within 1 minute of collection.
  • the integrated platform quickly separated plasma from whole blood, and the plasma proteins of interest were captured in the assay zone where DEAL barcode arrays were placed. This whole process from finger-prick to plasma protein capture took ⁇ 10 minutes.
  • the as-received serum samples were flowed into the integrated platforms without any pre-treatment (i.e. no purification or dilution).
  • a mixture of biotin-labeled detection antibodies ( ⁇ 50-100 nM) for the entire protein panel and the fluorescence Cy5-straptavidin conjugates ( ⁇ 100 nM) were flowed sequentially into the integrated platforms to complete the DEAL immunoassay.
  • the unbound fluorescence probes were rinsed off by flowing the buffer solution for 10 minutes.
  • the PDMS chip was removed from the glass slide.
  • the slide was immediately rinsed in 1 ⁇ 2 ⁇ PBS solution and deionized water, and then dried with a nitrogen gun.
  • the DEAL barcode slide was scanned by an Axon Instruments Genepix Scanner.
  • the serum samples from 24 cancer patients were assayed using two chips, each containing 12 separate assay units that were operated in parallel. In every assay unit, 50 sets of DEAL barcodes were placed in the detection channel for statistical sampling of the serum. In all experiments, 25 ⁇ L of patient serum, or 500 nanoliters per barcode, was used for each assay.
  • the white-blood cell secreted proteins included inflammatory molecules and cytokines. These proteins are employed by immune cells for intracellular communication, and have significant implications in tumor microenvironment formation, and in tumor progression and metastasis. Thus, this panel provides information on both cancer and the immune system.
  • FIGS. 24 and 25 show the related profile of cancer patients ( FIG. 24 ) together with their medical history ( FIG. 25 ).
  • fluorescence images each showing four sets of representative barcodes obtained from the 24 patient samples are shown in FIG. 24 .
  • the proteins measured include cancer marker PSA and eleven cytokines also indicated in details in FIG. 25 .
  • the left two columns were performed on the same chip while the right two were from the other.
  • the samples were randomly picked in the assay to minimize arbitrary bias.
  • B01-B11 denote 11 samples from breast cancer patients
  • P01-P11 denote those from prostate cancer patients
  • S01 and S02 are unknown samples from a different supplier.
  • FIG. 24 shows a brief summary of cancer patient medical records.
  • the two unknowns are not included in the table.
  • DNA-code Human Plasma Protein Abbreviation Panel (1) A/A′ Interferon-gamma IFN- ⁇ B/B′ Tumor necrosis factor-alpha TNF- ⁇ C/C′ Interleukin-2 IL-2 D/D′ Interleukin-1 alpha IL-1 ⁇ E/E′ Interleukin-1beta IL-1 ⁇ F/F′ Transforming growth factor beta TGF- ⁇ G/G′ Prostate specific antigen (total) PSA H/H′ Interleukin-6 IL-6 I/I′ Interleukin-10 IL-10 J/J′ Interleukin-12 IL-12 K/K′ Granulocyte-macrophage colony GM-CSF stimulating factor L/L′ Monocyte chemoattractant protein-1 MCP-1 M/M′ Blank control/reference Panel (2) AA/AA′ Interleukin-1 beta IL-1 ⁇ BB/BB′ Interleukin-6 IL-6 CC/CC′ Interleukin-10 IL-10 IL-10
  • the blood barcodes measured throughout the experiments illustrated in Example 10 were unique for each patient.
  • FIGS. 26 to 28 show quantitation and clustering of cancer patient barcode data obtained using a barcode array designed as exemplified in Example 8.
  • FIG. 26 shows layout of the barcode array used in this study.
  • Strand M denotes the reference (control).
  • FIG. 27 illustrates a plot showing quantitation of fluorescence signals of all proteins (left axis) detected as shown in FIG. 21A for all cancer patients (from left: B01-B11, P01-P11, S01 and S02).
  • S01 and S02 are two unknown serum samples.
  • FIG. 28 shows an exemplary manual clustering of cancer patients derived on the basis of protein patterns. First, all prostate cancer patients are clearly identified by PSA. Second, both breast and prostate cancer patients exhibit possible subpopulations with distinct cytokine profiles.
  • the fluorescence signals intensity for all the patient samples are plotted in FIG. 26 .
  • the cancer marker, PSA clearly distinguishes between the breast and prostate cancer patients, and allowed for the unknown samples, S01 and S02, to be assigned to prostate cancer patients.
  • Applicants then performed a manual clustering of patients on the basis of protein signals and generated the map schematically illustrated in FIG. 27 to assess the potential of this technology for patient stratification.
  • This approach is only going to be as good as the biomarker panel itself, and the number of serum samples profiled is small. Nevertheless, the results are encouraging.
  • the measured profiles of breast cancer patients can be classified into three subsets—non-inflammatory, IL-1 ⁇ positive, and TNF- ⁇ positive.
  • the prostate cancer patient data exhibits a generally higher level of inflammation, and those inflammation-positive samples can also be classified as shown in FIG. 27 .
  • An interesting observation is the lack of IL-10 signal for most patients.
  • IL-10 is a cytokine production suppressor that functions as an anti-inflammatory mediator, and its absence may reflect deviation from normal immune homeostasis in local tumor sites.
  • Applicants have initiated studies involving a larger number of proteins and a much larger number of blood samples. Researches have been focused on developing technologies for multiplexed measurement of cytokines, and serum cytokine profiling has shown relevance in cancer diagnostics and prognostics. The results described above have clearly demonstrated that integrated platforms can be applied to the multiparameter analysis of human health-relevant proteins.
  • the principal goal behind developing the integrated platform was to be able to measure the levels of a large number of proteins in human blood within a few minutes of sampling that blood, so as to avoid protein degradation that can occur when plasma is stored.
  • the biological sample of interest is added, and the protein diffuses to the surface-bound antibody. Under sufficient flow conditions, diffusion is no longer important, and the only parameter that limits the speed of the assay is the protein/antibody binding kinetics (the Langmuir isotherm), thus allowing the immunoassay to be completed in just a few minutes.
  • the human plasma proteome is comprised of three major classes of proteins—classical plasma proteins, tissue leakage proteins, and cell-cell signaling molecules (cytokines and chemokines).
  • Cell-cell signaling molecules are biologically informative in a variety of physiological and pathological processes, i.e. tumor host immunity and inflammation.
  • FIG. 29 shows detection of target protein other than cytokines TNF- ⁇ , and Interleukins such as IL-6, IL-10 is shown.
  • FIG. 29 shows detection of molecules such as CRP, C3 and plasminogen associated with biological profile such inflammation response (CRP), complement system (C3) and liver toxicity response (CRP and plasminogen).
  • CRP inflammation response
  • C3 complement system
  • C3 liver toxicity response
  • FIG. 30 The results of a second series of experiments performed by the Applicants is summarized in the diagram of FIG. 30 , showing a schematic of human plasma proteome (refer to N. L. Anderson and N. G. Anderson, Molecular & Cellular Proteomics 11, 845, 2001).
  • the concentration range of plasma proteins spans 12 orders of magnitude and the lowest end is approximately at the detection limit of mass spectrometry—a high-throughput protein profiling technique.
  • the state-of-the-art for clinical protein measurements is still the ELISA assay.
  • ELISA is a low-throughput process, requiring a large amount of sample and long duration to complete a multiparameter plasma protein measurement.
  • the high performance of the DEAL barcode chip, especially its increased sensitivity, is a key to realizing highly multiplexed measurements of a panel of proteins, including the low abundance cytokines, from small quantities of clinical blood samples.
  • the DEAL barcode assay has a markedly high sensitivity, comparable to ELISA, leading to the feasibility of multiplexed detection of plasma proteins including low-abundance cell-cell signaling molecules, e.g. cytokines and chemokines, from a small quantity of sample.
  • low-abundance cell-cell signaling molecules e.g. cytokines and chemokines
  • a DEAL immunoassay was used. To detect each protein, a pair of antibodies was chosen. One is conjugated to the secondary DNA strands that are complementary to the primary DNA strands flow-patterned on glass slides. This antibody also serves to capture proteins being detected, and then the biotin-labeled detection came in to bind to the same protein creating immunosandwich structure. Finally, Cy-3 or Cy5labled fluorescent streptavidin was used to visualize the results of bar-code through streptavidin-biotin binding.
  • Detection of human cytokine proteins prepared at different concentrations was first tested ( FIG. 15 ). The results show the detection is highly specific, and exhibits increased sensitivity comparable to ELISA. Then, a multiparameter (up to 5 proteins) detection was demonstrated as in FIG. 16 . TNF-a exhibits the best signal intensity due to the high affinity of the 10 anti-TNF-a AB. Having the high loading of primary DNA oligomers and by varying DNA concentrations in flow-pattering step, it is shown the a single bar-code can detect protein like hCG across a huge dynamic range, several orders of magnitube better than any conventional protein detection methods ( FIG. 21 ).
  • an integrated microfluidic device was fabricated, which comprises of a two-layer PDMS microfluidic chip bonded on to a bar-DEAL barcode glass chip, that allows rapid, sensitive detection of 13 different proteins at the same time out of 12 different human serum samples.
  • the DEAL bar-code devices for the first time provide a highly multiplexed (as in protein microarray and mass spectrometry) method for protein detection at an ultra-high sensitivity as good as the state-of-art ELISA assay.
  • Barcoded array patterning is a generic technique that can be exploited to pattern DNA, protein, or even sera and tissue lysates.
  • the inverse-phase bar-code array (serum or lysate array) can be used for high throughput drug screening and biomarker discovering.
  • FIG. 31 A schematic representation of a method to manufacture a magnetic ID barcode on a small object such as a ring is shown in FIG. 31 .
  • a PDMS microfluidic channels with a small exposed contact area can be manufactured using two-layer lithography (it means there are two layers of fluidic channels.
  • the bottom layer can be contacted with the substrate e.g. the small-sized product and the fluid can be introduced from the upper layer that contains embedded fluidic channels to join the bottom layer channels at the small contact area to the large inlets at the sides of the PDMS device.
  • the fabrication of magnetic barcode can be realized by simply immersing the small-sized subject patterned with DNA barcodes into a solution that contains several complementary DNA-magnetic nanoparticle conjugates.
  • the different combination of complementary DNA-magnetic nanoparticle conjugates gives rise to a distinct magnetic ID barcode that can be readily read with a magnetoresistive scan head.
US12/174,601 2007-07-16 2008-07-16 Arrays, substrates, devices, methods and systems for detecting target molecules Abandoned US20090036324A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/174,601 US20090036324A1 (en) 2007-07-16 2008-07-16 Arrays, substrates, devices, methods and systems for detecting target molecules
US14/694,340 US20160011189A1 (en) 2007-07-16 2015-04-23 Arrays, substrates, devices, methods and systems for detecting target molecules
US15/359,464 US10928389B2 (en) 2007-07-16 2016-11-22 Arrays, substrates, devices, methods and systems for detecting target molecules
US16/191,207 US20190195869A1 (en) 2007-07-16 2018-11-14 Arrays, substrates, devices, methods and systems for detecting target molecules

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95966607P 2007-07-16 2007-07-16
US99898107P 2007-10-15 2007-10-15
US12/174,601 US20090036324A1 (en) 2007-07-16 2008-07-16 Arrays, substrates, devices, methods and systems for detecting target molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/694,340 Continuation US20160011189A1 (en) 2007-07-16 2015-04-23 Arrays, substrates, devices, methods and systems for detecting target molecules

Publications (1)

Publication Number Publication Date
US20090036324A1 true US20090036324A1 (en) 2009-02-05

Family

ID=40260363

Family Applications (5)

Application Number Title Priority Date Filing Date
US12/174,598 Abandoned US20090053732A1 (en) 2007-07-16 2008-07-16 Microfluidic devices, methods and systems for detecting target molecules
US12/174,601 Abandoned US20090036324A1 (en) 2007-07-16 2008-07-16 Arrays, substrates, devices, methods and systems for detecting target molecules
US14/694,340 Abandoned US20160011189A1 (en) 2007-07-16 2015-04-23 Arrays, substrates, devices, methods and systems for detecting target molecules
US15/359,464 Active US10928389B2 (en) 2007-07-16 2016-11-22 Arrays, substrates, devices, methods and systems for detecting target molecules
US16/191,207 Abandoned US20190195869A1 (en) 2007-07-16 2018-11-14 Arrays, substrates, devices, methods and systems for detecting target molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US12/174,598 Abandoned US20090053732A1 (en) 2007-07-16 2008-07-16 Microfluidic devices, methods and systems for detecting target molecules

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/694,340 Abandoned US20160011189A1 (en) 2007-07-16 2015-04-23 Arrays, substrates, devices, methods and systems for detecting target molecules
US15/359,464 Active US10928389B2 (en) 2007-07-16 2016-11-22 Arrays, substrates, devices, methods and systems for detecting target molecules
US16/191,207 Abandoned US20190195869A1 (en) 2007-07-16 2018-11-14 Arrays, substrates, devices, methods and systems for detecting target molecules

Country Status (6)

Country Link
US (5) US20090053732A1 (fr)
EP (3) EP2167634A4 (fr)
JP (2) JP2010533869A (fr)
AU (2) AU2008276024A1 (fr)
CA (2) CA2694541A1 (fr)
WO (2) WO2009012340A2 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070259381A1 (en) * 2006-02-21 2007-11-08 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of reaction components that affect a reaction
US20090053732A1 (en) * 2007-07-16 2009-02-26 Ophir Vermesh Microfluidic devices, methods and systems for detecting target molecules
WO2009126828A3 (fr) * 2008-04-09 2010-03-04 California Institute Of Technology Agents de capture, et procédés et systèmes en rapport pour détecter et/ou trier des cibles
US20100075407A1 (en) * 2008-09-23 2010-03-25 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
US20100075862A1 (en) * 2008-09-23 2010-03-25 Quanterix Corporation High sensitivity determination of the concentration of analyte molecules or particles in a fluid sample
US20100140171A1 (en) * 2008-12-02 2010-06-10 Heath James Self-powered microfluidic devices, methods and systems
US20100279882A1 (en) * 2009-05-01 2010-11-04 Mostafa Ronaghi Sequencing methods
US20110039717A1 (en) * 2006-08-02 2011-02-17 Kwong Gabriel A Methods and systems for detecting and/or sorting targets
US20110166034A1 (en) * 2006-08-02 2011-07-07 Kwong Gabriel A Capture agents and related methods and systems for detecting and/or sorting targets
US20110195852A1 (en) * 2007-08-30 2011-08-11 Trustees Of Tufts College Methods for determining the concentration of an analyte in solution
US20110212848A1 (en) * 2010-03-01 2011-09-01 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US20110212537A1 (en) * 2010-03-01 2011-09-01 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US20110212462A1 (en) * 2010-03-01 2011-09-01 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
US20110294187A1 (en) * 2008-09-26 2011-12-01 The General Hospital Corporation Capturing particles
ITTO20100543A1 (it) * 2010-06-23 2011-12-24 Biodiversity S P A Dispositivo microfluidico integrato per la purificazione, amplificazione e rivelazione di acidi nucleici per la diagnostica
US20140242753A1 (en) * 2013-02-27 2014-08-28 Samsung Electronics Co., Ltd. Flip chip packaging method, and flux head manufacturing method applied to the same
WO2015089243A1 (fr) 2013-12-11 2015-06-18 The Regents For Of The University Of California Procédés de marquage de fragments d'adn pour la recontruction de liaison physique et de phase
US9110025B2 (en) 2010-03-01 2015-08-18 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US9252175B2 (en) 2011-03-23 2016-02-02 Nanohmics, Inc. Method for assembly of spectroscopic filter arrays using biomolecules
WO2016090148A1 (fr) 2014-12-03 2016-06-09 IsoPlexis Corporation Analyse et criblage de profils de sécrétion cellulaire
US9389231B2 (en) 2013-07-22 2016-07-12 Sandia Corporation Apparatus comprising magnetically actuated valves and uses thereof
WO2016196691A3 (fr) * 2015-06-01 2017-01-26 California Institute Of Technology Compositions et procédés pour l'analyse de lymphocytes t avec des antigènes pour des populations spécifiques
US9636675B2 (en) 2014-11-26 2017-05-02 International Business Machines Corporation Pillar array structure with uniform and high aspect ratio nanometer gaps
US9828696B2 (en) 2011-03-23 2017-11-28 Nanohmics, Inc. Method for assembly of analyte filter arrays using biomolecules
US9932626B2 (en) 2013-01-15 2018-04-03 Quanterix Corporation Detection of DNA or RNA using single molecule arrays and other techniques
US9952237B2 (en) 2011-01-28 2018-04-24 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
US9957554B1 (en) 2013-12-19 2018-05-01 National Technology & Engineering Solutions Of Sandia, Llc Microfluidic platform for multiplexed detection in single cells and methods thereof
US9995411B1 (en) 2014-07-16 2018-06-12 National Technology & Engineering Solutions Of Sandia, Llc High-temperature, adhesive-based microvalves and uses thereof
US10094762B2 (en) * 2013-05-30 2018-10-09 UNIVERSITé LAVAL Patterned capillary device and process for fabricating thereof
US10386351B2 (en) 2015-12-07 2019-08-20 Nanohmics, Inc. Methods for detecting and quantifying analytes using gas species diffusion
US10386365B2 (en) 2015-12-07 2019-08-20 Nanohmics, Inc. Methods for detecting and quantifying analytes using ionic species diffusion
US10393759B2 (en) 2011-04-12 2019-08-27 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US10983116B2 (en) 2012-08-24 2021-04-20 Yale University System, device and method for high-throughput multi-plexed detection
US11237171B2 (en) 2006-02-21 2022-02-01 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
WO2022217731A1 (fr) * 2021-04-16 2022-10-20 杭州浙大迪迅生物基因工程有限公司 Kit de mesure quantitative utilisant une puce fluorescente
US11493508B2 (en) 2016-11-11 2022-11-08 IsoPlexis Corporation Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
JP2009536313A (ja) 2006-01-11 2009-10-08 レインダンス テクノロジーズ， インコーポレイテッド ナノリアクターの形成および制御において使用するマイクロ流体デバイスおよび方法
EP2530168B1 (fr) 2006-05-11 2015-09-16 Raindance Technologies, Inc. Dispositifs microfluidiques
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
WO2008021123A1 (fr) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Tensioactifs fluorocarbonés stabilisateurs d'émulsions
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US9222936B2 (en) 2007-04-18 2015-12-29 Solulink, Inc. Methods and/or use of oligonucleotide conjugates for suppressing background due to cross-hybridization
WO2008130623A1 (fr) 2007-04-19 2008-10-30 Brandeis University Manipulation de fluides, composants fluidiques et réactions dans des systèmes microfluidiques
US8306773B2 (en) * 2007-08-29 2012-11-06 Canon U.S. Life Sciences, Inc. Microfluidic devices with integrated resistive heater electrodes including systems and methods for controlling and measuring the temperatures of such heater electrodes
US9221056B2 (en) * 2007-08-29 2015-12-29 Canon U.S. Life Sciences, Inc. Microfluidic devices with integrated resistive heater electrodes including systems and methods for controlling and measuring the temperatures of such heater electrodes
US8380457B2 (en) * 2007-08-29 2013-02-19 Canon U.S. Life Sciences, Inc. Microfluidic devices with integrated resistive heater electrodes including systems and methods for controlling and measuring the temperatures of such heater electrodes
JP5163999B2 (ja) * 2007-11-14 2013-03-13 国立大学法人富山大学 類似植物体および生薬同定用ｄｎａマイクロアレイ
WO2010009365A1 (fr) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Bibliothèque de gouttelettes
WO2010085548A2 (fr) * 2009-01-22 2010-07-29 Li-Cor, Inc. Protéomique sur molécules individuelles avec des sondes dynamiques
WO2010099318A1 (fr) * 2009-02-27 2010-09-02 Yale University Préparation d'échantillon physiologique pour nanodétecteurs
US9739771B2 (en) 2009-02-27 2017-08-22 Yale University Physiologic sample preparation for nanosensors
EP3415235A1 (fr) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation de gouttelettes microfluidiques
WO2011042564A1 (fr) 2009-10-09 2011-04-14 Universite De Strasbourg Nanomatériau marqué à base de silice à propriétés améliorées et ses utilisations
US9700889B2 (en) 2009-11-23 2017-07-11 Cyvek, Inc. Methods and systems for manufacture of microarray assay systems, conducting microfluidic assays, and monitoring and scanning to obtain microfluidic assay results
CN102713621B (zh) * 2009-11-23 2016-10-19 西维克公司 用于施行化验的方法和设备
US9500645B2 (en) 2009-11-23 2016-11-22 Cyvek, Inc. Micro-tube particles for microfluidic assays and methods of manufacture
US9855735B2 (en) 2009-11-23 2018-01-02 Cyvek, Inc. Portable microfluidic assay devices and methods of manufacture and use
US10065403B2 (en) 2009-11-23 2018-09-04 Cyvek, Inc. Microfluidic assay assemblies and methods of manufacture
US9651568B2 (en) 2009-11-23 2017-05-16 Cyvek, Inc. Methods and systems for epi-fluorescent monitoring and scanning for microfluidic assays
US9759718B2 (en) 2009-11-23 2017-09-12 Cyvek, Inc. PDMS membrane-confined nucleic acid and antibody/antigen-functionalized microlength tube capture elements, and systems employing them, and methods of their use
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
JP5934657B2 (ja) 2010-02-12 2016-06-15 レインダンス テクノロジーズ， インコーポレイテッド デジタル検体分析
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
WO2011106198A1 (fr) 2010-02-23 2011-09-01 Christopher Gordon Atwood Procédés de détection de molécules biologiquement pertinentes et leurs caractéristiques d'interaction
US8614056B2 (en) 2010-03-24 2013-12-24 The Board Of Trustees Of The Leland Stanford Junior University Microfluidic method for measurement or detection involving cells or biomolecules
JP2011221009A (ja) * 2010-03-25 2011-11-04 Fujifilm Corp 生体物質検出装置
KR101152791B1 (ko) * 2010-05-10 2012-06-12 광주과학기술원 쯔바이파흐-풍 효과를 이용한 세포 발열량 측정 센서 및 이의 제조방법
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
EP3447155A1 (fr) * 2010-09-30 2019-02-27 Raindance Technologies, Inc. Dosages en sandwich dans des gouttelettes
WO2012109600A2 (fr) 2011-02-11 2012-08-16 Raindance Technologies, Inc. Procédés de formation de gouttelettes mélangées
EP2675819B1 (fr) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions et méthodes de marquage moléculaire
CN106552682B (zh) 2011-03-22 2020-06-19 西维克公司 微流体装置以及制造方法和用途
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2714970B1 (fr) 2011-06-02 2017-04-19 Raindance Technologies, Inc. Quantification d'enzyme
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013060482A1 (fr) * 2011-10-28 2013-05-02 Torsten Matthias Dispositif et procédé de détection de substances présentes dans des prélèvements biologiques ou chimiques
EP2822689B1 (fr) 2012-03-08 2023-07-26 Cyvek, Inc. Particules micro-tubulaires pour analyses microfluidiques et procédés de fabrication
US10145842B2 (en) 2012-04-11 2018-12-04 Quidel Cardiovascular Inc. Microfluidic device, system and method
WO2014083496A1 (fr) 2012-11-29 2014-06-05 Koninklijke Philips N.V. Cartouche de prélèvement et traitement d'échantillon
US9386948B2 (en) 2012-12-05 2016-07-12 Theranos, Inc. Systems, devices, and methods for bodily fluid sample transport
US10248765B1 (en) 2012-12-05 2019-04-02 Theranos Ip Company, Llc Systems, devices, and methods for bodily fluid sample collection, transport, and handling
CA3153763A1 (en) 2013-03-11 2014-10-09 Meso Scale Technologies, Llc. Improved methods for conducting multiplexed assays
US20140323911A1 (en) * 2013-03-15 2014-10-30 Theranos, Inc. Methods and devices for sample collection and sample separation
EP2971280B1 (fr) 2013-03-15 2018-08-29 Arizona Board of Regents on behalf of Arizona State University Compositions et procédés de microréseaux de biocapteurs
KR101428977B1 (ko) 2013-06-14 2014-08-13 케이맥(주) 미세유체 분석장치
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
WO2015103367A1 (fr) 2013-12-31 2015-07-09 Raindance Technologies, Inc. Système et procédé de détection d'une espèce d'arn
WO2016209775A1 (fr) * 2015-06-20 2016-12-29 The Regents Of The University Of California Dosage microfluidique basé sur des intégrines de monocytes destiné à l'évaluation de maladies coronaires
US10371606B2 (en) 2015-07-21 2019-08-06 Theraos IP Company, LLC Bodily fluid sample collection and transport
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
US11247208B2 (en) 2015-09-09 2022-02-15 Labrador Diagnostics Llc Methods and devices for sample collection and sample separation
US10498171B2 (en) * 2015-10-12 2019-12-03 Avago Technologies International Sales Pte. Limited Wireless power receiver voltage control enabling simultaneous communications to transmitter in over-voltage state
US10228367B2 (en) 2015-12-01 2019-03-12 ProteinSimple Segmented multi-use automated assay cartridge
JP2019528810A (ja) * 2016-07-07 2019-10-17 ヴァンダービルト ユニヴァーシティ 疾患材料の検出、捕捉、または除去のための流体デバイス
WO2018058085A1 (fr) * 2016-09-26 2018-03-29 The Johns Hopkins University Détection et analyse de cancers non invasifs par imagerie monomoléculaire
EP3545284A4 (fr) 2016-11-22 2020-07-01 Isoplexis Corporation Systèmes, dispositifs et procédés de capture de cellules et procédés de fabrication correspondants
CN110520541B (zh) 2017-02-13 2024-03-26 耶鲁大学 高通量单细胞多组学
US10850276B2 (en) * 2017-02-24 2020-12-01 VisuGen Global LLC Systems and methods for capture and detection of low copy targets from large sample volumes
WO2018156855A1 (fr) * 2017-02-24 2018-08-30 VisuGen Global LLC Systèmes et procédés de capture et de détection de cibles à faible nombre de copies à partir de grands volumes d'échantillons
US11857966B1 (en) 2017-03-15 2024-01-02 Labrador Diagnostics Llc Methods and devices for sample collection and sample separation
WO2018183969A1 (fr) * 2017-03-30 2018-10-04 California Institute Of Technology Plate-forme de dosage rapide à code-barres pour l'analyse efficace de molécules candidates et procédés de préparation et d'utilisation de la plate-forme
WO2018194700A1 (fr) 2017-04-20 2018-10-25 Hewlett-Packard Development Company, L.P. Système de réaction microfluidique
WO2019036055A2 (fr) 2017-08-18 2019-02-21 Ignite Biosciences, Inc. Procédés de sélection de réactifs de liaison
ES2702432B2 (es) 2017-08-31 2019-08-05 Venegas Pedro Manuel Medina Método y dispositivo para el análisis de ácidos nucleicos
KR101906969B1 (ko) 2017-09-15 2018-10-11 삼성전자주식회사 유전자 분석장치 및 이를 이용한 유전자 분석방법
US11890620B2 (en) 2017-10-13 2024-02-06 The Charles Stark Draper Laboratory, Inc. Miniaturized DNA microarray for small-volume sample processing
WO2019147714A1 (fr) * 2018-01-23 2019-08-01 Shield Diagnostics Corp. Dispositifs et procédés de microréseau microfluidique
CN108588284B (zh) * 2018-05-10 2022-06-10 山东师范大学 基于酶催化可控自组装生物条码检测htlv-ii dna的方法
CN109387641B (zh) * 2018-12-20 2022-04-15 深圳职业技术学院 一种以磁性氧化铁纳米粒子为信号放大器检测天蚕素b的装置及检测方法
US20220146399A1 (en) * 2019-02-27 2022-05-12 Kyocera Corporation Particle separating and measuring device and particle separating and measuring apparatus
CN110026258B (zh) * 2019-04-26 2023-11-28 珠海市迪奇孚瑞生物科技有限公司 基于数字微流控芯片的检测电路、装置及dna或rna检测装置
US11130994B2 (en) * 2019-12-13 2021-09-28 Autonomous Medical Devices Inc. Automated, cloud-based, point-of-care (POC) pathogen and antibody array detection system and method
WO2022178253A1 (fr) 2021-02-19 2022-08-25 IsoPlexis Corporation Procédés et dispositifs d'analyse à résolution spatiale d'informations protéomiques et génétiques
US11505796B2 (en) 2021-03-11 2022-11-22 Nautilus Biotechnology, Inc. Systems and methods for biomolecule retention
US11543332B2 (en) * 2021-04-23 2023-01-03 Poppy Health, Inc. System and method for characterizing, monitoring, and detecting bioaerosol presence and movement in an indoor environment

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039897A (en) * 1996-08-28 2000-03-21 University Of Washington Multiple patterned structures on a single substrate fabricated by elastomeric micro-molding techniques
US20020146745A1 (en) * 2001-04-03 2002-10-10 Surromed, Inc. Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
US20030013091A1 (en) * 2001-07-03 2003-01-16 Krassen Dimitrov Methods for detection and quantification of analytes in complex mixtures
US6524790B1 (en) * 1997-06-09 2003-02-25 Caliper Technologies Corp. Apparatus and methods for correcting for variable velocity in microfluidic systems
US20030082601A1 (en) * 2001-08-30 2003-05-01 Killian Dill Enzyme-amplified redox microarray detection process
US6924153B1 (en) * 1997-03-06 2005-08-02 Quidel Corporation Quantitative lateral flow assays and devices
US20060263818A1 (en) * 2005-05-23 2006-11-23 Axel Scherer High throughput multi-antigen microfluidic fluorescence immunoassays
US20070074972A1 (en) * 2005-09-13 2007-04-05 Fluidigm Corporation Microfluidic assay devices and methods
US20070122819A1 (en) * 2005-11-25 2007-05-31 Industrial Technology Research Institute Analyte assay structure in microfluidic chip for quantitative analysis and method for using the same
US20090017455A1 (en) * 2006-08-02 2009-01-15 Kwong Gabriel A Methods and systems for detecting and/or sorting targets

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6943034B1 (en) * 1991-11-22 2005-09-13 Affymetrix, Inc. Combinatorial strategies for polymer synthesis
US6632436B2 (en) * 1996-01-25 2003-10-14 Genitrix Llc Vaccine compositions and method of modulating immune responses
US6165739A (en) 1996-03-13 2000-12-26 Compucyte Corporation Multiple simultaneous testing media
US5858801A (en) * 1997-03-13 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Patterning antibodies on a surface
US20030096232A1 (en) * 1997-12-19 2003-05-22 Kris Richard M. High throughput assay system
US6316193B1 (en) * 1998-10-06 2001-11-13 Origene Technologies, Inc. Rapid-screen cDNA library panels
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US6875619B2 (en) * 1999-11-12 2005-04-05 Motorola, Inc. Microfluidic devices comprising biochannels
US20020090649A1 (en) * 1999-12-15 2002-07-11 Tony Chan High density column and row addressable electrode arrays
US6699665B1 (en) 2000-11-08 2004-03-02 Surface Logix, Inc. Multiple array system for integrating bioarrays
WO2002044695A1 (fr) * 2000-11-16 2002-06-06 Burstein Technologies, Inc. Methodes et appareils destines a la detection et au denombrement de lymphocytes utilisant des biodisques optiques
JP2002236131A (ja) * 2000-12-08 2002-08-23 Minolta Co Ltd マイクロチップ
US20020100714A1 (en) * 2001-01-31 2002-08-01 Sau Lan Tang Staats Microfluidic devices
US20020168640A1 (en) * 2001-02-22 2002-11-14 Min Li Biochips comprising nucleic acid/protein conjugates
DE10127221A1 (de) * 2001-05-23 2002-11-28 Lifebits Ag Träger für chemische, biochemische und biologische Substanzen
US7023007B2 (en) * 2001-07-17 2006-04-04 Caliper Life Sciences, Inc. Methods and systems for alignment of detection optics
US7258837B2 (en) * 2001-12-05 2007-08-21 University Of Washington Microfluidic device and surface decoration process for solid phase affinity binding assays
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
AU2002952384A0 (en) * 2002-10-31 2002-11-14 Swinburne University Of Technology Structures
JP2004354364A (ja) * 2002-12-02 2004-12-16 Nec Corp 微粒子操作ユニット、それを搭載したチップと検出装置、ならびにタンパク質の分離、捕獲、および検出方法
DE10305050A1 (de) * 2003-02-07 2004-08-19 Roche Diagnostics Gmbh Analytisches Testelement und Verfahren für Blutuntersuchungen
EP1594992A2 (fr) * 2003-02-19 2005-11-16 Syntherica Corporation Compositions et procedes de criblage utilisant des populations d'anticorps de substitution
US7452678B2 (en) * 2003-06-24 2008-11-18 Bristol-Myers Squibb Company Identification of biomarkers for liver toxicity
AU2004258101B2 (en) * 2003-07-03 2010-12-23 Gentron, Llc Methods and systems for diagnosis of non-central nervous system (CNS) diseases in CNS samples
WO2005043154A2 (fr) * 2003-10-27 2005-05-12 Massachusetts Institute Of Technology Chambres de réaction haute densité et procédés d'utilisation
US7981362B2 (en) * 2003-11-04 2011-07-19 Meso Scale Technologies, Llc Modular assay plates, reader systems and methods for test measurements
JP4814103B2 (ja) * 2003-11-12 2011-11-16 バイオ−ラッド・ハイファ・リミテッド アレイフォーマットにおいて複数の結合反応を実行するためのシステムおよび方法
KR20070004725A (ko) * 2004-02-20 2007-01-09 더 리전츠 오브 더 유니버시티 오브 캘리포니아 타액 ｍＲＮＡ 프로파일링, 생물 마커 및 관련 방법 및부품 키트
ATE527059T1 (de) * 2004-03-18 2011-10-15 Nissui Pharm Co Ltd Methode zur herstellung einer analytischen vorrichtung und kit
CN1296492C (zh) 2004-11-18 2007-01-24 博奥生物有限公司 一种基于生物芯片检测能结合特异序列的核酸结合蛋白的方法
EP1838880A2 (fr) * 2005-01-21 2007-10-03 Third Wave Technologies, Inc. Procédés et compositions pour détection à plage dynamique augmentée de molécules d'acide nucléique
GB0508983D0 (en) * 2005-05-03 2005-06-08 Oxford Gene Tech Ip Ltd Cell analyser
US20060286549A1 (en) * 2005-05-06 2006-12-21 The Regents Of The University Of California Microfluidic system for identifying or sizing individual particles passing through a channel
JP2006329767A (ja) * 2005-05-25 2006-12-07 Aisin Seiki Co Ltd 試料分析装置
WO2007011622A2 (fr) * 2005-07-18 2007-01-25 U.S. Genomics, Inc. Procedes microfluidiques et dispositifs de preparation et d'analyse d'echantillons
CA2616404A1 (fr) 2005-07-26 2007-02-01 Oregon Health & Science University Sondes nanoparticulaires pour capturer, trier et placer des cibles
US7776553B2 (en) 2005-09-16 2010-08-17 Presidents And Fellows Of Harvard College Screening assays and methods
MX342351B (es) 2005-12-21 2016-09-26 Meso Scale Technologies Llc Modulos de ensayo que tienen reactivos de ensayo y metodos para hacer y utilizar los mismos.
AU2007212306A1 (en) * 2006-02-07 2007-08-16 Wafergen, Inc. Temperature-regulated culture plates
WO2008101196A1 (fr) * 2007-02-15 2008-08-21 Osmetech Molecular Diagnostics Dispositifs fluidiques
EP2167634A4 (fr) 2007-07-16 2013-11-06 California Inst Of Techn Réseaux, substrats, dispositifs, procédés et systèmes pour la détection de molécules cibles
EP4148118A1 (fr) 2012-08-24 2023-03-15 Yale University Système, dispositif et procédé de détection multiplexée à haut rendement
US9824870B1 (en) * 2014-04-29 2017-11-21 The United States Of America As Represented By The Administrator Of Nasa Portable medical diagnosis instrument

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6039897A (en) * 1996-08-28 2000-03-21 University Of Washington Multiple patterned structures on a single substrate fabricated by elastomeric micro-molding techniques
US6924153B1 (en) * 1997-03-06 2005-08-02 Quidel Corporation Quantitative lateral flow assays and devices
US6524790B1 (en) * 1997-06-09 2003-02-25 Caliper Technologies Corp. Apparatus and methods for correcting for variable velocity in microfluidic systems
US20020146745A1 (en) * 2001-04-03 2002-10-10 Surromed, Inc. Methods and reagents for multiplexed analyte capture, surface array self-assembly, and analysis of complex biological samples
US20030013091A1 (en) * 2001-07-03 2003-01-16 Krassen Dimitrov Methods for detection and quantification of analytes in complex mixtures
US20030082601A1 (en) * 2001-08-30 2003-05-01 Killian Dill Enzyme-amplified redox microarray detection process
US20060263818A1 (en) * 2005-05-23 2006-11-23 Axel Scherer High throughput multi-antigen microfluidic fluorescence immunoassays
US20070074972A1 (en) * 2005-09-13 2007-04-05 Fluidigm Corporation Microfluidic assay devices and methods
US20070122819A1 (en) * 2005-11-25 2007-05-31 Industrial Technology Research Institute Analyte assay structure in microfluidic chip for quantitative analysis and method for using the same
US20090017455A1 (en) * 2006-08-02 2009-01-15 Kwong Gabriel A Methods and systems for detecting and/or sorting targets

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Inerowicz et al. ((Langmuir, 2002, vol. 18, pgs., 5263-5268, "Multiprotein immunoassay arrays fabricated by microcontact printing"), *
Ivanova, et al. (Langmuir, 2002, vol. 18, pgs. 9539-9546, "Polymer microstructures fabricated via laser ablation used for multianalyte protein microassay"), *
Wegner et al. (Analytical Chemistry, 2003, vol. 75, pgs. 4740-4746, "Fabrication of Histidine-Tagged Fusion Protein Arrays for Surface Plasmon Resonance Imaging Studies of Protein-Protein and Protein-DNA Interactions). *

Cited By (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11874279B2 (en) 2006-02-21 2024-01-16 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US20070259385A1 (en) * 2006-02-21 2007-11-08 The Trustees Of Tufts College Methods and arrays for detecting cells and cellular components in small defined volumes
US9395359B2 (en) 2006-02-21 2016-07-19 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US20070259381A1 (en) * 2006-02-21 2007-11-08 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of reaction components that affect a reaction
US8492098B2 (en) 2006-02-21 2013-07-23 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of reaction components that affect a reaction
US8460879B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US8460878B2 (en) 2006-02-21 2013-06-11 The Trustees Of Tufts College Methods and arrays for detecting cells and cellular components in small defined volumes
US10261089B2 (en) 2006-02-21 2019-04-16 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US11237171B2 (en) 2006-02-21 2022-02-01 Trustees Of Tufts College Methods and arrays for target analyte detection and determination of target analyte concentration in solution
US8394590B2 (en) 2006-08-02 2013-03-12 California Institute Of Technology Capture agents and related methods and systems for detecting and/or sorting targets
US20110039717A1 (en) * 2006-08-02 2011-02-17 Kwong Gabriel A Methods and systems for detecting and/or sorting targets
US20110166034A1 (en) * 2006-08-02 2011-07-07 Kwong Gabriel A Capture agents and related methods and systems for detecting and/or sorting targets
US8354231B2 (en) 2006-08-02 2013-01-15 Cal. Inst. Tech. Methods and systems for detecting and/or sorting targets
US10928389B2 (en) * 2007-07-16 2021-02-23 California Institute Of Technology Arrays, substrates, devices, methods and systems for detecting target molecules
US20090053732A1 (en) * 2007-07-16 2009-02-26 Ophir Vermesh Microfluidic devices, methods and systems for detecting target molecules
US20170138942A1 (en) * 2007-07-16 2017-05-18 California Institute Of Technology Arrays, substrates, devices, methods and systems for detecting target molecules
US20110195852A1 (en) * 2007-08-30 2011-08-11 Trustees Of Tufts College Methods for determining the concentration of an analyte in solution
US9809838B2 (en) 2007-08-30 2017-11-07 Trustees Of Tufts College Methods for determining the concentration of an analyte in solution
WO2009126828A3 (fr) * 2008-04-09 2010-03-04 California Institute Of Technology Agents de capture, et procédés et systèmes en rapport pour détecter et/ou trier des cibles
US8222047B2 (en) 2008-09-23 2012-07-17 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
US20100075862A1 (en) * 2008-09-23 2010-03-25 Quanterix Corporation High sensitivity determination of the concentration of analyte molecules or particles in a fluid sample
US20100075407A1 (en) * 2008-09-23 2010-03-25 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
US8846415B2 (en) 2008-09-23 2014-09-30 Quanterix Corporation Ultra-sensitive detection of molecules on single molecule arrays
US10126218B2 (en) 2008-09-26 2018-11-13 The General Hospital Corporation Capturing particles
US9128091B2 (en) * 2008-09-26 2015-09-08 The General Hospital Corporation Capturing particles
US20110294187A1 (en) * 2008-09-26 2011-12-01 The General Hospital Corporation Capturing particles
US20100140171A1 (en) * 2008-12-02 2010-06-10 Heath James Self-powered microfluidic devices, methods and systems
US8557199B2 (en) 2008-12-02 2013-10-15 California Institute Of Technology Self-powered microfluidic devices, methods and systems
WO2010065661A1 (fr) 2008-12-02 2010-06-10 California Institute Of Technology Dispositifs microfluidiques à alimentation autonome, procédés et systèmes
US20100279882A1 (en) * 2009-05-01 2010-11-04 Mostafa Ronaghi Sequencing methods
WO2010127304A3 (fr) * 2009-05-01 2011-05-05 Illumina, Inc. Procédés de séquençage
US9678068B2 (en) 2010-03-01 2017-06-13 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
US9482662B2 (en) 2010-03-01 2016-11-01 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US20110212848A1 (en) * 2010-03-01 2011-09-01 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US9310360B2 (en) 2010-03-01 2016-04-12 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US11619631B2 (en) 2010-03-01 2023-04-04 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US20110212537A1 (en) * 2010-03-01 2011-09-01 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US9110025B2 (en) 2010-03-01 2015-08-18 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US9846155B2 (en) 2010-03-01 2017-12-19 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US9551663B2 (en) 2010-03-01 2017-01-24 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US10989713B2 (en) 2010-03-01 2021-04-27 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
US20110212462A1 (en) * 2010-03-01 2011-09-01 Quanterix Corporation Ultra-sensitive detection of molecules using dual detection methods
US10725032B2 (en) 2010-03-01 2020-07-28 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US8236574B2 (en) 2010-03-01 2012-08-07 Quanterix Corporation Ultra-sensitive detection of molecules or particles using beads or other capture objects
US8415171B2 (en) 2010-03-01 2013-04-09 Quanterix Corporation Methods and systems for extending dynamic range in assays for the detection of molecules or particles
ITTO20100543A1 (it) * 2010-06-23 2011-12-24 Biodiversity S P A Dispositivo microfluidico integrato per la purificazione, amplificazione e rivelazione di acidi nucleici per la diagnostica
US11112415B2 (en) 2011-01-28 2021-09-07 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
US11977087B2 (en) 2011-01-28 2024-05-07 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
US9952237B2 (en) 2011-01-28 2018-04-24 Quanterix Corporation Systems, devices, and methods for ultra-sensitive detection of molecules or particles
US9252175B2 (en) 2011-03-23 2016-02-02 Nanohmics, Inc. Method for assembly of spectroscopic filter arrays using biomolecules
US10550494B2 (en) 2011-03-23 2020-02-04 Nanohmics, Inc. Method for assembly of analyte filter arrays using biomolecules
US9828696B2 (en) 2011-03-23 2017-11-28 Nanohmics, Inc. Method for assembly of analyte filter arrays using biomolecules
US10393759B2 (en) 2011-04-12 2019-08-27 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US11275092B2 (en) 2011-04-12 2022-03-15 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US10983116B2 (en) 2012-08-24 2021-04-20 Yale University System, device and method for high-throughput multi-plexed detection
US10640814B2 (en) 2013-01-15 2020-05-05 Quanterix Corporation Detection of DNA or RNA using single molecule arrays and other techniques
US9932626B2 (en) 2013-01-15 2018-04-03 Quanterix Corporation Detection of DNA or RNA using single molecule arrays and other techniques
US20140242753A1 (en) * 2013-02-27 2014-08-28 Samsung Electronics Co., Ltd. Flip chip packaging method, and flux head manufacturing method applied to the same
US9263414B2 (en) * 2013-02-27 2016-02-16 Samsung Electronics Co., Ltd. Flip chip packaging method, and flux head manufacturing method applied to the same
US10094762B2 (en) * 2013-05-30 2018-10-09 UNIVERSITé LAVAL Patterned capillary device and process for fabricating thereof
US10126299B2 (en) 2013-07-22 2018-11-13 National Technology & Engineering Solutions Of Sandia, Llc Amplification of biological targets via on-chip culture for biosensing
US9389231B2 (en) 2013-07-22 2016-07-12 Sandia Corporation Apparatus comprising magnetically actuated valves and uses thereof
US9857370B2 (en) 2013-07-22 2018-01-02 National Technology & Engineering Solutions Of Sandia, Llc Amplification of biological targets via on-chip culture for biosensing
EP3540074A1 (fr) 2013-12-11 2019-09-18 The Regents of the University of California Procédé de marquage de régions internes de molécules d'acid nucléique
WO2015089243A1 (fr) 2013-12-11 2015-06-18 The Regents For Of The University Of California Procédés de marquage de fragments d'adn pour la recontruction de liaison physique et de phase
US9957554B1 (en) 2013-12-19 2018-05-01 National Technology & Engineering Solutions Of Sandia, Llc Microfluidic platform for multiplexed detection in single cells and methods thereof
US10731205B2 (en) 2013-12-19 2020-08-04 National Technology & Engineering Solutions Of Sandia, Llc Microfluidic platform for multiplexed detection in single cells and methods thereof
US9995411B1 (en) 2014-07-16 2018-06-12 National Technology & Engineering Solutions Of Sandia, Llc High-temperature, adhesive-based microvalves and uses thereof
US9636675B2 (en) 2014-11-26 2017-05-02 International Business Machines Corporation Pillar array structure with uniform and high aspect ratio nanometer gaps
WO2016090148A1 (fr) 2014-12-03 2016-06-09 IsoPlexis Corporation Analyse et criblage de profils de sécrétion cellulaire
US11066689B2 (en) * 2014-12-03 2021-07-20 IsoPlexis Corporation Analysis and screening of cell secretion profiles
US10584366B2 (en) 2014-12-03 2020-03-10 IsoPlexis Corporation Analysis and screening of cell secretion profiles
US20230138672A1 (en) * 2014-12-03 2023-05-04 IsoPlexis Corporation Analysis and screening of cell secretion profiles
US11661619B2 (en) 2014-12-03 2023-05-30 IsoPlexis Corporation Analysis and screening of cell secretion profiles
US11353448B2 (en) 2015-02-13 2022-06-07 California Institute Of Technology Methods and compositions for quantifying metabolites and proteins from single cells
WO2016196691A3 (fr) * 2015-06-01 2017-01-26 California Institute Of Technology Compositions et procédés pour l'analyse de lymphocytes t avec des antigènes pour des populations spécifiques
KR102489353B1 (ko) 2015-06-01 2023-01-17 캘리포니아 인스티튜트 오브 테크놀로지 특정 집단에 대한 항원으로 t 세포를 스크리닝하기 위한 조성물 및 방법
EP3303635A4 (fr) * 2015-06-01 2019-01-16 California Institute of Technology Compositions et procédés pour l'analyse de lymphocytes t avec des antigènes pour des populations spécifiques
US10481158B2 (en) 2015-06-01 2019-11-19 California Institute Of Technology Compositions and methods for screening T cells with antigens for specific populations
KR20180014769A (ko) * 2015-06-01 2018-02-09 캘리포니아 인스티튜트 오브 테크놀로지 특정 집단에 대한 항원으로 t 세포를 스크리닝하기 위한 조성물 및 방법
US10386365B2 (en) 2015-12-07 2019-08-20 Nanohmics, Inc. Methods for detecting and quantifying analytes using ionic species diffusion
US10386351B2 (en) 2015-12-07 2019-08-20 Nanohmics, Inc. Methods for detecting and quantifying analytes using gas species diffusion
US11493508B2 (en) 2016-11-11 2022-11-08 IsoPlexis Corporation Compositions and methods for the simultaneous genomic, transcriptomic and proteomic analysis of single cells
WO2022217731A1 (fr) * 2021-04-16 2022-10-20 杭州浙大迪迅生物基因工程有限公司 Kit de mesure quantitative utilisant une puce fluorescente

Also Published As

Publication number Publication date
WO2009012343A2 (fr) 2009-01-22
US20090053732A1 (en) 2009-02-26
EP2167634A4 (fr) 2013-11-06
US20170138942A1 (en) 2017-05-18
CA2694545C (fr) 2019-10-01
WO2009012343A9 (fr) 2010-02-04
EP2167633A4 (fr) 2014-12-24
CA2694545A1 (fr) 2009-01-22
US20160011189A1 (en) 2016-01-14
WO2009012340A2 (fr) 2009-01-22
JP2010533871A (ja) 2010-10-28
JP2010533869A (ja) 2010-10-28
EP2167633A2 (fr) 2010-03-31
CA2694541A1 (fr) 2009-01-22
WO2009012340A3 (fr) 2009-03-26
AU2008276027B2 (en) 2014-09-04
EP2167634A2 (fr) 2010-03-31
AU2008276024A1 (en) 2009-01-22
AU2008276027A1 (en) 2009-01-22
EP3628729A2 (fr) 2020-04-01
EP3628729A3 (fr) 2020-05-06
US10928389B2 (en) 2021-02-23
WO2009012343A3 (fr) 2009-04-23
US20190195869A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
US10928389B2 (en) Arrays, substrates, devices, methods and systems for detecting target molecules
Fan et al. Integrated barcode chips for rapid, multiplexed analysis of proteins in microliter quantities of blood
US6929944B2 (en) Analysis using a distributed sample
US8586348B2 (en) Lateral flow microfluidic assaying device and related method
US8124015B2 (en) Multiplexed, microfluidic molecular assay device and assay method
US10302640B2 (en) Image differentiated multiplex assays
AU5625399A (en) Method and measuring device for determining a plurality of analytes in a sample
Araz et al. Microfluidic multiplexing in bioanalyses
US20100298163A1 (en) Microfluidic microarray system and method for the multiplexed analysis of biomolecules
US20020127740A1 (en) Quantitative microfluidic biochip and method of use
Roh et al. Microfluidic fabrication of encoded hydrogel microparticles for application in multiplex immunoassay
Kersten et al. Multiplex approaches in protein microarray technology
US20220397528A1 (en) Systems and methods for rapid, sensitive multiplex immunoassays
JP2004527735A5 (fr)
JP2004527735A (ja) タンパク質特性を検出するための生化学的方法及び装置
US20080311679A1 (en) Biosensor Device
Lee et al. Intensity Histogram-Based Reliable Image Analysis Method for Bead-Based Fluorescence Immunoassay
US20080160623A1 (en) Method and device for bioanalyte quantification by on/off kinetics of binding complexes
WO2009150583A1 (fr) Dispositif de diagnostic
US20070224702A1 (en) Flex Method
Haroun et al. Development of the immunoassay of antibodies and cytokines on nanobioarray chips
CN113687061A (zh) 基于虚拟分割方法的生物靶标数字化定量检测系统
Ahmad Microfluidics Platforms for Quantitative, Multiplexed Protein Detection
EP1996946A1 (fr) Procédé plex
QINGDI Microparticle Array on Gel Microstructure Chip for Multiplexed Biochemical Assays

Legal Events

Date Code Title Description
AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE;ASSIGNOR:CALIFORNIA INSTITUTE OF TECHNOLOGY;REEL/FRAME:021334/0959

Effective date: 20080804

AS Assignment

Owner name: CALIFORNIA INSTITUTE OF TECHNOLOGY, CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FAN, RONG;AHMAD, HABIB;HEATH, JAMES R.;REEL/FRAME:021699/0260

Effective date: 20080723

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION